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ORIGINAL CONTRIBUTIONSAdjuncts for the evaluation of
potentially malignant disorders
in the oral cavity
Diagnostic test accuracy systematic review and
meta-analysis—a report of the American Dental
AssociationABSTRACT
Background. Oral squamous cell carcinoma is the most common
manifestation of malignancy in the oral cavity. Adjuncts are available for
clinicians to evaluate lesions that seem potentially malignant. In this sys-
tematic review, the authors summarized the available evidence on patient-
important outcomes, diagnostic test accuracy (DTA), and patients’ values
and preferences (PVPs) when using adjuncts for the evaluation of clinically
evident lesions in the oral cavity.
Types of Studies Reviewed. The authors searched for preexisting
systematic reviews and assessed their quality using the Assessing the
Methodological Quality of Systematic Reviews tool. The authors updatedMark W. Lingen, DDS, PhD, FRCPath;
Malavika P. Tampi, MPH; Olivia Urquhart,
MPH; Elliot Abt, DDS, MS, MSc; Nishant
Agrawal, MD; Anil K. Chaturvedi, PhD; Ezra
Cohen, MD, FRCPSC; Gypsyamber D’Souza,
PhD; JoAnn Gurenlian, RDH, PhD; John R.
Kalmar, DMD, PhD; Alexander R. Kerr, DDS,
MSD; Paul M. Lambert, DDS; Lauren L.
Patton, DDS; Thomas P. Sollecito, DMD, FDS,
RCS; Edmond Truelove, DDS, MSD; Laura
Banfield, MLIS, MHS; Alonso Carrasco-Labra,
DDS, MScthe selected reviews and searched MEDLINE, Embase, and the Cochrane
Central Register of Controlled Trials to identify randomized controlled
trials and DTA and PVPs studies. Pairs of reviewers independently con-
ducted study selection, data extraction, and assessment of the certainty in
the evidence by using the Grading of Recommendations Assessment,
Development and Evaluation approach.
Results. The authors identified 4 existing reviews. DTA reviews included
37 studies. The authors retrieved 7,534 records, of which 9 DTA and 10
PVPs studies were eligible. Pooled sensitivity and specificity of adjuncts
ranged from 0.39 to 0.96 for the evaluation of innocuous lesions and fromI n 2017, an estimated 49,670 new casesof cancer in the oral cavity andpharynx will be diagnosed in theUnited States, with 9,700 disease-
associated deaths.1 Estimates for cancer in
the oral cavity alone include 32,670 new
cases and 6,650 deaths.1 Most of these
cancers will be squamous cell carcinomas.Copyright ª 2017 American Dental Assoc
rights reserved.
0.31 to 0.95 for the evaluation of suspicious lesions. Cytologic testing used
in suspicious lesions appears to have the highest accuracy among adjuncts
(sensitivity, 0.92; 95% confidence interval, 0.86 to 0.98; specificity, 0.94; 95%
confidence interval, 0.88 to 0.99; low-quality evidence).Survival
is highly
stage
depen-Conclusions and Practical Implications. Cytologic testing appears
to be the most accurate adjunct among those included in this review. The
main concerns are the high rate of false-positive results and serious issues of
risk of bias and indirectness of the evidence. Clinicians should remain
skeptical about the potential benefit of any adjunct in clinical practice.
Key Words. Oral squamous cell carcinoma; potentially malignant dis-
orders; diagnostic test accuracy; patients’ values and preferences.dent, with 83.7% of people surviving 5
years after diagnosis of localized cancer
and 64.2% and 38.5% of people surviving
with regional and distant metastases.2
Approximately 70% of all new cases
are diagnosed at a late stage, under-
scoring the importance of proper patientiation. All
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ABBREVIATION KEY. ADA: American Dental Association.
CDC: Centers for Disease Control and Prevention. CVTE:
Conventional visual and tactile examination. DTA: Diagnostic
test accuracy. GRADE: Grading of Recommendations Assess-
ment, Development and Evaluation. OSCC: Oral squamous
cell carcinoma. PMD: Potentially malignant disorder. PVPs:
Patients’ values and preferences. RCT: Randomized controlled
trial.
ORIGINAL CONTRIBUTIONSevaluation for the prevention or early detection of dis-
ease.1 Clinicians detect and assess oral potentially ma-
lignant disorders (PMDs) and oral squamous cell
carcinomas (OSCCs) by using the combination of an
intra- and extraoral conventional visual and tactile
examination and the detection of dysplasia through tis-
sue biopsy. However, although as many as 10% of pa-
tients will have some type of oral mucosal abnormality,
only a small fraction of these abnormalities or lesions will
be biologically and clinically significant.3
Conventional visual and tactile examination in the
oral cavity is limited in its ability to help discriminate
between similar-appearing lesions or disorders that may
require considerably different treatments. To address
analogous challenges at other anatomic sites, clinicians
have used adjunctive tests or devices, simply known as
adjuncts, such as mammography, the Papanicolaou
smear, and colonoscopy, to assist in the detection and
evaluation of disease. A number of adjuncts have become
commercially available to aid in the evaluation and
discrimination of oral mucosal lesions.4-8 These adjuncts
can be divided into 3 broad categories: lesion detection or
discrimination, lesion assessment, and risk assessment.
- Lesion detection or discrimination. This category is
composed mostly of light-based handheld adjuncts pro-
posed to aid clinicians in the detection and margin
discrimination of lesions by using the principles of
autofluorescence and tissue reflectance. Some also would
classify vital staining within this category.
- Lesion assessment. This category of adjuncts is
intended to assist clinicians in assessing the biological or
clinical relevance of a mucosal abnormality through
cytomorphologic analysis of disaggregated epithelial cells
(cytologic testing). Some also would classify vital staining
within this category.
-Risk assessment. This category is composed of saliva-
based adjuncts that involve using a number of bio-
markers, including proteins, RNAs, and DNAs.
The purpose of this systematic review was to address
the potential benefits and limitations of commercially
available adjuncts to aid in the detection, discrimination,
and assessment of oral mucosal lesions, particularly
PMDs and OSCC in adult patients. This article is an
update and major revision of the 2010 review6 which was
performed by an expert panel of clinical and subject
matter experts convened by the American Dental Asso-
ciation (ADA) Council on Scientific Affairs. The ADA
Center for Evidence-Based Dentistry and the Cochrane
Collaboration provided methodological support for the
development and authorship of this review.
Adjuncts can be incorporated in the diagnostic
pathway to triage before an existing test, replace an
existing test, or add on to an existing test to increase
accuracy.9 For this systematic review, we interpreted data
from the included studies in the context of using
adjuncts to triage the need for biopsy and not as798 JADA 148(11) http://jada.ada.org November 2017replacement for biopsy.10 Clinicians typically use triage
tools in an early stage of the diagnostic process to
identify patients with a particular finding that will be
informative for subsequent steps in the testing pathway.
These findings informed the development of a 2017
evidence-based clinical practice guideline by the ADA
Center for Evidence-Based Dentistry,11 which contains
recommendation statements to guide the clinical
decision-making process (eTable 1).
METHODS
This report follows the guidance of the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses12 statement and other methodological rec-
ommendations from the Cochrane Screening and
Diagnostic Tests Methods Group.13
Selection criteria for the studies in this review.
Type of studies. We included cross-sectional and cohort
diagnostic test accuracy (DTA) studies and randomized
controlled trials (RCTs) in which the investigators
assessed the effectiveness or accuracy of adjuncts. We
excluded study designs such as case-control studies, case
reports, case series, abstracts, and uncontrolled reports.
Type of participants and target conditions. Studies
eligible for inclusion involved adult patients (aged 18
years or older), ideally in the context of primary care
settings, seeking care with or without clinically evident
lesions in the oral cavity, encompassing the labial
mucosae, buccal mucosae, gingival or alveolar ridge
mucosae, tongue, floor of mouth, hard and soft palate,
and retromolar trigone. If clinically evident, lesions could
manifest as seemingly innocuous or nonsuspicious, sus-
picious, or seemingly malignant. We excluded studies
involving patients seeking care for cancers of the lips,
oropharynx, and salivary glands.
Index tests and the criterion standard. Definitive
diagnosis of PMDs and OSCC requires using a criterion
standard wherein the patient undergoes a biopsy of the
lesion followed by a histopathologic assessment. Studies
not specifying any criterion standard were ineligible for
inclusion in this systematic review. Other tests, devices,
techniques, or technologies intended to facilitate clinical
decision making are index tests. The aforementioned
adjuncts act as index tests in the context of this review
and are used as triage tools in practice. Adjuncts can
have either a positive (with suspicion of target condition)
ORIGINAL CONTRIBUTIONSor negative (without suspicion of target condition) test
result.
We defined several adjuncts of interest a priori and
assessed them regarding their DTA and effectiveness
when evaluating patients with
- no clinically evident lesions in the oral cavity;
- clinically evident seemingly innocuous or nonsuspi-
cious lesions in the oral cavity;
- clinically evident suspicious lesions or seemingly
malignant lesions in the oral cavity.
Adjuncts include the following:
- cytologic testing (for example, OralCDx [OralScan
Laboratories, Inc.], OralCyte [ClearCyte Diagnostics
Inc.], ClearPrep OC [Resolution Biomedical]);
- autofluorescence (for example, VELscope [LED
Dental], OralID [Forward Science]); tissue reflectance
(for example, ViziLite Plus [DenMat Holdings, LLC],
Microlux DL [AdDent Inc.]);
- vital staining (for example, toluidine blue);
- salivary adjuncts (for example, OraRisk [Oral DNA
Labs], SaliMark [PeriRx LLC], OraMark [OncAlert
Labs], MOP genetic oral cancer screening [PCG Molec-
ular], OraGenomics);
- additional adjuncts of interest (for example, Identafi
[StarDental]).
We also included combinations of aforementioned
adjuncts if 1 adjunct informed the use of the second
adjunct. We reported results separately if the in-
vestigators used 2 index tests in a study independently of
each other. We excluded adjuncts not commercially
available in the United States at the date of the search.
Types of outcomes and estimates. Patient-important
outcomes are defined as “outcomes for which—even if it
were the only outcome improved by the intervention—
the patient would still consider receiving the intervention
in face of some adverse events, costs, and burden.”14-16 In
the context of adjuncts, patients will prioritize outcomes
such as morbidity and mortality and serious adverse
events over other surrogate outcomes such as DTA
estimates. We defined the following patient-important
outcomes a priori and included all-cause mortality,
OSCC mortality, survival, quality of life, unnecessary
biopsy, costs, incidence of OSCC, and anxiety and stress.
DTA estimates defined a priori included sensitivity,
specificity, and positive and negative likelihood ratios.
We used the proportion of true-positive, true-negative,
false-positive, and false-negative results to calculate DTA
estimates. We excluded studies when reporting made it
impossible to create a contingency table.
Positivity thresholds. As stated in the Cochrane
Handbook for Diagnostic Test Accuracy Reviews, “binary
test outcomes are defined on the basis of a threshold for
test positivity and change if the threshold is altered.”13
Whenever possible, we considered all levels of oral
epithelial dysplasia (mild, moderate, and severe) assessed
during biopsy or histopathologic assessment as positivefor the target condition and absence of dysplasia assessed
during biopsy or histopathologic assessment as negative
for the target condition. For cytologic testing adjuncts,
we grouped any atypical results with dysplastic results
when possible and considered them positive for the
target condition.
Using preexisting evidence. As a way to optimize the
development of systematic reviews to inform ADA
guidelines, we established a collaboration with the
Cochrane Oral Health Group. The purpose of this
collaboration was to increase efficiency in the use of
secondary evidence for the development of clinical
practice guidelines by using preexisting high-quality
systematic reviews. In the event that no Cochrane
reviews were available, we searched for non-Cochrane
systematic reviews.
The eligible reviews had to meet 3 criteria. The first
was being assessed as having moderate to high meth-
odological quality. The second was being as current as
possible. The third was meeting the selection criteria in
relation to the type of study design, patient characteris-
tics, index tests, criterion standard, and outcomes.
Identifying relevant systematic reviews. We identi-
fied eligible systematic reviews through our collaboration
with the Cochrane Oral Health Group. Members of the
group suggested Cochrane reviews that potentially met
our selection criteria. When no Cochrane reviews were
available for a specific clinical question, we searched for
non-Cochrane reviews by using the PubMed Clinical
Queries tool and prioritized the most current ones (from
2010 to the present). To determine final eligibility, we
used the Assessing the Methodological Quality of Sys-
tematic Reviews tool to assess their methodological
quality.17
Literature search to update existing reviews and
linked evidence on patient-important outcomes. With
the purpose of updating potentially eligible existing re-
views, we searched MEDLINE via Ovid, Embase via
Ovid, and the Cochrane Central Register of Controlled
Trials. We included all study designs in the initial search.
We also added economic analysis and patients’ values
and preferences (PVPs). After reviewing the results, we
deemed it necessary to rerun the related Cochrane
searches. We rebuilt the Cochrane searches for Embase,
MEDLINE, and the Cochrane Central Register of
Controlled Trials. We then restricted that language to
RCTs, systematic reviews, and meta-analyses as a means
of ensuring the update of the Cochrane review and to
inform the patient-important outcomes (linked evi-
dence) of interest. Given that literature related to salivary
adjuncts was limited within the bounds of the existing
searches, we removed study design considerations to
open up the possibilities of finding relevant language. We
restricted the updated Cochrane searches from April 2013
(latest update by Cochrane) to December 2016. We
ran the search on economic analysis and PVPs fromJADA 148(11) http://jada.ada.org November 2017 799
ORIGINAL CONTRIBUTIONSinception to November 2016. The amended search for
salivary adjuncts was run from April 2013 (latest update
by Cochrane) to February 2017 (Appendix 1, available
online at the end of this article). We did not apply re-
strictions on language or publication status.
Selection of primary studies for update of system-
atic reviews and data extraction. We conducted the
study selection process in 3 phases. In the first phase, 2
reviewers (M.P.T., O.U.) independently reassessed eligi-
bility of all included studies in the 20154 and 20135
Cochrane reviews. In the second phase, the same 2
reviewers independently screened titles and abstracts of
retrieved references from the updated search strategy for
both DTA studies and RCTs. In the third phase,
reviewers independently screened the full text of all
potentially eligible studies. We resolved any disagree-
ments at full-text level via discussion and consensus.
When consensus was elusive, a third reviewer (A.C.L.)
arbitrated and decided final eligibility. For information
about the data extraction process, see Appendix 2
(available online at the end of this article).
Summary measures of DTA and patient-important
outcomes at a study level. DTA studies included in
this review reported results in contingency tables as a
cross-classification of target condition status (condition
present or absent determined by using the criterion
standard) and the adjunct’s outcome (condition positive
or negative determined by means of the index test).13 We
presented data as true-positive, false-positive, true-
negative, and false-negative results. We then calculated
summary measures of DTA such as sensitivity, speci-
ficity, and positive and negative likelihood ratios along
with their 95% confidence intervals (CIs). Sensitivity and
specificity are measures defined as conditional on the
disease status, whereas likelihood ratios can be used to
update the pretest probability of disease to the posttest
probability once the test result is known.18 We planned
on obtaining the prevalence of PMDs and OSCC in the
US adult population and using sensitivity and specificity
to calculate absolute measures. For patient-important
outcomes reported dichotomously, we planned to pre-
sent their results by using relative risks and their 95%
CIs. For continuous outcomes, we considered the use of a
mean difference, the standard deviation, and the 95% CI
as summary measures.
Assessment of the risk of bias of included studies.
Similar to methods used in other Cochrane systematic
reviews on DTA, we used a modified version of the
QUADAS-2 tool19 to assess the risk of bias and appli-
cability of primary diagnostic accuracy studies included
in our review. Two reviewers (M.P.T., O.U.) used the
tool independently and in duplicate. We assessed the
following domains in each study: patient selection, index
test, criterion standard, and flow and timing. We
assessed all domains in terms of the risk of bias by using
signaling questions to assist in the judgments. We also800 JADA 148(11) http://jada.ada.org November 2017assessed the first 3 domains in terms of their applica-
bility. Other important considerations for the quality
assessment included representativeness of the study
sample, extent of verification bias, use of blinded
methods for interpreting test results, and presence of
missing data.13
Data synthesis and meta-analysis. We recorded the
number of true-positive, false-positive, true-negative, and
false-negative results by using software (Review Man-
ager, Version 5.3, Cochrane Collaboration). We recorded
all new events at the lesion level to mirror the data
presented in the 2015 Cochrane review.4 For each study,
we displayed estimates of DTA, sensitivity, and speci-
ficity, along with their 95% CIs, in coupled forest plots, as
well as plotted in summary receiver operating charac-
teristic curve space according to index test. We per-
formed meta-analysis to obtain pooled estimates for
sensitivity, specificity, and positive and negative likeli-
hood ratios for each adjunct by using the bivariate
approach13 (SAS, Version 9.4, SAS Institute). When too
few studies were available for pooling by using the
bivariate approach, we obtained the pooled estimate by
combining their contingency tables for the associated
comparison. We acknowledge that this method may have
a tendency to create artificially narrower CIs. However,
considering that this review is informing a clinical
practice guideline, we prioritized the presentation of
pooled estimates to facilitate decision making.
Assessment of the quality of the evidence. We
assessed the quality of the evidence for all included
outcomes by using the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
approach with specification for the diagnostic test
context.20 The GRADE approach provides a framework
to assess the degree of confidence we can place in DTA
and patient-important outcomes. In GRADE, cross-
sectional or cohort studies in patients with diagnostic
uncertainty and a comparison with an appropriate cri-
terion standard start as high-quality evidence (high
certainty in the evidence). Our certainty is reduced,
however, when these studies have serious issues such as
risk of bias or limitations in study design, indirectness,
inconsistency, imprecision, or high probability of publi-
cation bias (eTable 2).21 Such issues move the quality of
the evidence from high to moderate, low, or very low
certainty. We presented data in summary-of-findings
tables created using software (GRADEpro Guideline
Development Tool, McMaster University and Evidence
Prime). For a detailed description of the methods used to
assess heterogeneity, publication bias, and the planned
sensitivity analysis, see Appendix 2 (available online at
the end of this article).
RESULTS
Results of the search. We identified 2 Cochrane re-
views4,5 in which the investigators reported on DTA for
Records identified through
database searching
(n = 7,534)
Records screened
(n = 6,708)
Records excluded
(n = 6,614)
Duplicates removed
(n = 824)
Full-text articles
excluded (n = 85)
Studies identified from
existing systematic reviews
(n = 37 [38 articles])
Full-text articles assessed for
eligibility (n = 94)
Studies included  from
updating process
(n = 9)
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses12 flow chart of the screening and
study selection process.
ORIGINAL CONTRIBUTIONSadjuncts in patients both
with and without clini-
cally evident lesions
developed by the
Cochrane Oral Health
Group. In addition,
we identified 2 non-
Cochrane reviews
covering the use of
salivary adjuncts.22,23
From the 2015
Cochrane review, we
identified 37 studies that
were eligible.4 From the
2013 Cochrane review, no
primary studies met our
selection criteria.5 The
other 2 non-Cochrane
systematic reviews were
published in 2016 and
2017 and covered salivary
adjuncts for the early
diagnosis of OSCC, and
no updating process was
required.22,23During the updating process of the evidence from
these reviews, we identified 7,534 references from the
electronic databases. After eliminating duplicates, we
screened the titles and abstracts of 6,708 citations. We
selected 94 potentially eligible articles that we then
screened using full texts. Of the 94 full-text articles, we
selected 9 studies as part of the updating process and
excluded the remaining 85 (eTable 3,4 available online at
the end of this article). This resulted in a total of 46
included studies (47 reports) (Figure 1).4,12 No studies on
salivary adjuncts met our selection criteria, so we per-
formed a comprehensive search to identify published
systematic reviews.
During the process of identifying studies on PVPs, we
identified 2,616 citations and included 59 of those for
full-text screening. Finally, 10 studies were eligible.
Investigators in none of the studies reported on the
relative importance of outcomes in the context of the use
of adjuncts for the evaluation of PMDs.
Characteristics of included studies. DTA studies. In
the 46 included studies, the investigators enrolled a total
of 4,543 participants ranging in age from 18 through 80
years, conducted the studies between 1980 and 2016, and
reported data on the diagnostic accuracy of the following
adjuncts: autofluorescence,24-31 cytologic testing,32-47 vital
staining,42,48-61 tissue reflectance,24,62-66 tissue reflectance
and vital staining,28,62,65,67,68 and cytologic testing and vital
staining.69,70 Investigators had conducted most studies
in secondary24,26-28,30-34,36,37,41,44-47,49-51,53,55-62,65,67,68,70 or
tertiary25,29,35,39,40,43,48,54,57,63,64 care settings and in the
United Kingdom,24,49,66 Italy,30,39,40,48 Germany,26,27,31,34,35,43Spain,45,50 Taiwan,52 China,53,54 Iran,32 the United
States,44,46,55,58,62,67 Australia,25,63,64 Turkey,69
India,28,36,37,42,47,51,56,59,61,65,70 Poland,68 Japan,29 Brazil,33,57
Canada,41 Sri Lanka,38,60 or Pakistan.60 The target con-
dition for all studies encompassed PMDs or OSCC
(eTable 4).24-70
Investigators in many of the included primary
studies did not disclose any conflicts of interest and
sources of funding, though a few provided information
regarding links to industry funding and grants for
research.33,40,44,46,52,54,60,67,69 We identified no studies in
which the investigators assessed patient-important
outcomes such as all-cause mortality, OSCC mortality,
survival time, quality of life, costs, incidence of OSCC,
and anxiety or stress, and none met our selection
criteria.
PVPs studies. One systematic review71 and 9 primary
studies72-80 including 1,950 participants provided infor-
mation about patients’ perspective, barriers, and facili-
tators during the evaluation of PMDs. For a detailed
description of the included studies and results, see
eTable 571-80 and Appendix 2 (available online at the end
of this article).
Determination of prevalence of disease. We were
unable to identify data on the prevalence of PMDs and
OSCC in theUS population in the published literature.We
contacted the Centers for Disease Control and Prevention,
National Institute for Dental and Craniofacial Research,
and National Cancer Institute to determine whether
they had this information. Although these agencies were
unable to give us an accurate estimate, we built ourJADA 148(11) http://jada.ada.org November 2017 801
TABLE 1
Autofluorescence adjuncts to evaluate clinically evident, seemingly innocuous,
or nonsuspicious lesions.*
TEST RESULT DOWNSTREAM CONSEQUENCES EFFECT PER 100,000 PATIENTS TESTED
(95% CONFIDENCE INTERVAL [CI])
NUMBER
OF
LESIONS
(STUDIES)
QUALITY
OF THE
EVIDENCE
(GRADE)§Prevalence 0.25%
† Prevalence 2%‡
True Positives
(Patients With Need
for Biopsy)
Patients will be correctly identified as
having a potentially malignant or
malignant disorder and a timely referral
to a specialist or biopsywill be carriedout.
125 (53 to 198) 1,000 (420 to 1,580)
156 (1) Low¶,#,**False Negatives
(Patients Incorrectly
Classified as Not
Having Need for
Biopsy)
Appropriate diagnostic would be missed,
worsening the prognosis of the disease.
125 (52 to 197) 1,000 (420 to 1,580)
True Negatives
(Patients Without
Need for Biopsy)
Patients will receive reassurance that
they do not have a potentially malignant
or malignant disorder.
38,903 (30,923 to 46,883) 38,220 (30,380 to 46,060)
156 (1) Low¶,#,**False Positives
(Patients Incorrectly
Classified as Having
Need for Biopsy)
Patients would be incorrectly identified
as having a potentially malignant or
malignant disorder and would undergo
additional unnecessary testing and
biopsy.
60,847 (52,867 to 68,827) 59,780 (51,940 to 67,620)
* Setting: primary care. Sensitivity, 0.50 (95% confidence interval [CI], 0.21 to 0.79). Specificity, 0.39 (95% CI, 0.31 to 0.47). Positive likelihood ratio,
0.82 (95% CI, 0.46 to 1.46). Negative likelihood ratio, 1.29; (95% CI, 0.70 to 2.35). Source: Mehrotra and colleagues.28
† We estimated the prevalence by using data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program (300,682
people living with oral cavity and pharynx cancer in the United States in 2013) and the 2010 census data for adults 45 years or older collected by the
US Census Bureau.
‡ The panel provided illustrative prevalence as an estimation of the number of histopathologic diagnoses from dysplasia to cancer.
§ GRADE: Grading of Recommendations Assessment, Development and Evaluation.
¶ We judged the patient selection and index test domains as being at high risk of bias.
# The investigators conducted the study in a secondary care setting. Most patients had a higher probability of having a malignant or potentially
malignant disorder.
** The positivity threshold for the reference test was unclear.
ORIGINAL CONTRIBUTIONSprevalence estimate by using the 2013 Surveillance,
Epidemiology, and End Results Program data from the
National Cancer Institute and 2010 census data for people
45 years or older to calculate and obtain an estimated
prevalence of OSCC in the United States of 0.25%.81,82 We
recognized that this estimate did not include PMDs, so we
used an estimate of 2.0% to illustrate the potential preva-
lence of PMDs andOSCC in an attempt to account for this
limitation in current available data.
Risk of bias of included reviews. We identified 4
preexisting systematic reviews meeting the selection
criteria for the clinical questions included in this
review.4,5,22,23 For more information, see eTables 6
through 94,5,16,22,23 and Appendix 2 (available online at
the end of this article).
Risk of bias of primary studies. Poor reporting did
not allow us to conduct a complete risk of bias
assessment for many of the included studies. Across
the domains of patient selection, index test, and cri-
terion standard, we determined that approximately
50% of the included studies were unclear. For the flow
and timing domains, reporting quality was much
higher, and we considered them as the domains of
least concern from a risk of bias perspective. There802 JADA 148(11) http://jada.ada.org November 2017were almost no applicability issues among the studies
(eFigure 125-70 and eFigure 2, available online at the
end of this article).
DTA of adjuncts. Because no studies in which the
investigators assessed patient-important outcomes met
our selection criteria, we used DTA estimates as surro-
gate outcomes.
Evidence assessing the use of adjuncts to evaluate
patients with no clinically evident lesions. The authors
of the 2013 Cochrane review5 found no studies informing
the accuracy and effect of adjuncts. In our update of this
preexisting review, we also failed to identify studies
meeting our selection criteria. The panel thought it was
important to include the best available evidence for this
patient scenario and thus decided to amend the selection
criteria for salivary adjuncts to include case-control
studies. Systematic reviews conducted in 2016 and 2017
met this new selection criterion and summarized the
available evidence on the potential use of salivary adjuncts
for the early diagnosis of OSCC and malignant disor-
ders.22,23 Most of the studies we identified were
diagnostic-test case-control studies, followed by a few
cross-sectional and prospective studies. The sampling
methods to collect saliva varied across studies
TABLE 2
Cytologic adjuncts to evaluate clinically evident, seemingly innocuous, or
nonsuspicious lesions.*
TEST RESULT DOWNSTREAM CONSEQUENCES§ EFFECT PER 100,000 PATIENTS TESTED
(95% CONFIDENCE INTERVAL [CI])
NUMBER
OF
LESIONS
(STUDIES)
QUALITY
OF THE
EVIDENCE
(GRADE)Prevalence 0.25%
† Prevalence 2%‡
True Positives
(Patients With Need
for Biopsy)
Patients will be correctly identified as
having a potentially malignant or
malignant disorder and a timely referral
to a specialist or biopsy will be carried
out.
240 (203 to 250) 1,920 (1,620 to 2,000)
79 (1) Low¶,#,**
False Negatives
(Patients Incorrectly
Classified as Not
Having Need for
Biopsy)
Appropriate diagnostic would be missed,
worsening the prognosis of the disease.
10 (0 to 47) 80 (0 to 380)
True Negatives
(Patients Without
Need for Biopsy)
Patients will receive reassurance that
they do not have a potentially malignant
or malignant disorder.
89,775 (78,803 to 96,758) 88,200 (77,420 to 95,060)
79 (1) Low¶,#,**False Positives
(Patients Incorrectly
Classified as Having
Need for Biopsy)
Patients would be incorrectly identified
as having a potentially malignant or
malignant disorder and would undergo
additional unnecessary testing and
biopsy.
9,975 (2,992 to 20,947) 9,800 (2,940 to 20,580)
* Setting: primary care. Sensitivity, 0.96 (95% confidence interval [CI], 0.81 to 1.00). Specificity, 0.90 (95% CI, 0.79 to 0.97). Positive likelihood ratio,
10.01 (95% CI, 4.34 to 23.12). Negative likelihood ratio, 0.04 (95% CI, 0.01 to 0.28). Source: Mehrotra and colleagues.36
† We estimated the prevalence by using data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program (300,682
people living with oral cavity and pharynx cancer in the United States in 2013) and the 2010 census data for adults 45 years or older collected by the
US Census Bureau.
‡ The panel provided illustrative prevalence as an estimation of the number of histopathologic diagnoses from dysplasia to cancer.
§ GRADE: Grading of Recommendations Assessment, Development and Evaluation.
¶ The sampling method, the positivity threshold for dysplasia in regard to the reference standard, and to what extent examiners were calibrated
during interpretation of the index test are unclear.
# The investigators conducted the study in a secondary care setting. Most patients had a higher probability of having a malignant or potentially
malignant disorder.
** The positivity threshold for the index test included atypical results.
ORIGINAL CONTRIBUTIONS(unstimulated saliva or oral rinse), and most of them were
assessed as being of low or moderate methodological
quality.23 Most studies had small sample sizes with fewer
than 100 participants, although a few studies were
larger.22,23
Most biomarkers showed a wide range of DTA results
(sensitivity ranging from 0.5-0.9 and specificity ranging
from 0.63-0.90).22 Some biomarkers were clearly shown
not to be associated with the presence of early PMDs and
did not suggest the ability to inform disease progres-
sion.22 In contrast, other biomarkers were elevated
significantly in those with OSCC compared with those
without OSCC.23
We acknowledge that people with no clinically
evident lesions and those with clinically evident lesions
deemed seemingly innocuous or nonsuspicious
(as opposed to populations with suspicious lesions,
which primarily were included in these reviews) are
the ones who may benefit the most if these adjuncts
show improved DTA in the future.
Evidence assessing the use of adjuncts to evaluate
patients with clinically evident, seemingly innocuous
(nonsuspicious) lesions or symptoms. We identified 2studies28,36 in which the investigators addressed the DTA
of autofluorescence, cytologic testing, and tissue reflec-
tance and vital staining in patients with seemingly
innocuous or nonsuspicious lesions. Pooled sensitivity
and specificity of adjuncts ranged from 0.39 to 0.96 for
the evaluation of innocuous lesions. eTable 424-70 sum-
marizes the characteristics of the included populations,
and investigators conducted all studies in a secondary or
tertiary care setting.
Autofluorescence. One study informed this compari-
son with the investigators evaluating data from 156
lesions.28 The positivity threshold for the criterion
standard was unclear (eTable 10,24-70 available online at
the end of this article). When a clinician uses auto-
fluorescence, 50% of lesions with the target condition will
be identified correctly as positive by using the adjuncts
(sensitivity, 0.50; 95% CI, 0.21 to 0.79). However, 39% of
lesions without the target condition will be identified
correctly as negative by using the adjuncts (specificity,
0.39; 95% CI, 0.31 to 0.47) (eFigure 3,28 available online at
the end of this article). See Table 1,28 which includes
additional absolute measures calculated using an
illustrative PMD and OSCC prevalence of 2.0%.JADA 148(11) http://jada.ada.org November 2017 803
TABLE 3
Tissue reflectance and vital staining adjuncts to evaluate clinically evident,
seemingly innocuous, or nonsuspicious lesions.*
TEST RESULT DOWNSTREAM CONSEQUENCES EFFECT PER 100,000 PATIENTS TESTED (95%
CONFIDENCE INTERVAL [CI])
NUMBER
OF
LESIONS
(STUDIES)
QUALITY
OF THE
EVIDENCE
(GRADE)§Prevalence 0.25%
† Prevalence 2%‡
True Positives
(Patients With Need
for Biopsy)
Patients will be correctly identified as
having a potentially malignant or
malignant disorder and a timely referral
to a specialist or biopsy will be carried
out.
0 (0 to 150) 0 (0 to 1,200)
102 (1) Low¶,#,**
False Negatives
(Patients Incorrectly
Classified as Not
Having Need for
Biopsy)
Appropriate diagnostic would be missed,
worsening the prognosis of the disease.
250 (100 to 250) 2,000 (800 to 2,000)
True Negatives
(Patients Without
Need for Biopsy)
Patients will receive reassurance that
they do not have a potentially malignant
or malignant disorder.
75,810 (65,835 to 83,790) 74,480 (64,680 to 82,320)
102 (1) Low¶,#,**False Positives
(Patients Incorrectly
Classified as Having
Need for Biopsy)
Patients would be incorrectly identified
as having a potentially malignant or
malignant disorder and would undergo
additional unnecessary testing and
biopsy.
23,940 (15,960 to 33,915) 23,520 (15,680 to 33,320)
* Setting: primary care. Sensitivity, 0.00 (95% confidence interval [CI], 0.00 to 0.60). Specificity, 0.76 (95% CI, 0.66 to 0.84). Positive likelihood ratio,
not available. Negative likelihood ratio, 1.32 (95% CI, 1.18 to 1.48). Source: Mehrotra and colleagues.28
† We estimated the prevalence by using data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program (300,682
people living with oral cavity and pharynx cancer in the United States in 2013) and the 2010 census data for adults 45 years or older collected by the
US Census Bureau.
‡ The panel provided illustrative prevalence as an estimation of the number of histopathologic diagnoses from dysplasia to cancer.
§ GRADE: Grading of Recommendations Assessment, Development and Evaluation.
¶ We judged the patient selection and index test domains as being at high risk of bias.
# The investigators conducted the study in a secondary care setting. Most patients had a higher probability of having a malignant or potentially
malignant disorder.
** The positivity threshold for the reference test in regard to dysplasia was unclear.
ORIGINAL CONTRIBUTIONSCytologic testing. One study informed this compari-
son with the investigators evaluating data from 79
lesions.36 The positivity threshold for the criterion stan-
dard was unclear (eTable 10,24-70 available online at the
end of this article). When clinicians use cytologic testing,
96% of lesions with the target condition will be identified
correctly as positive by using the adjunct (sensitivity,
0.96; 95% CI, 0.81 to 1.00). However, 90% of lesions
without the target condition will be identified correctly as
negative by using the adjunct (specificity, 0.90; 95% CI,
0.79 to 0.97) (eFigure 4,36 available online at the end of
this article). See Table 2,36 which includes additional
absolute measures calculated using an illustrative PMD
and OSCC prevalence of 2.0%.
Tissue reflectance and vital staining. One study
informed this comparison with the investigators evalu-
ating data from 102 lesions.28 The positivity threshold for
the criterion standard was unclear (eTable 10,24-70 avail-
able online at the end of this article). When a clinician
uses tissue reflectance and vital staining, 0% of lesions
with the target condition will be identified correctly as
positive by using the adjunct (sensitivity, 0.00; 95% CI,
0.00 to 0.60). However, 76% of lesions without the
disorder will be identified correctly as negative by using804 JADA 148(11) http://jada.ada.org November 2017the adjunct (specificity, 0.76; 95% CI, 0.66 to 0.84)
(eFigure 5,28 available online at the end of this article).
See Table 3,28 which includes additional absolute mea-
sures calculated using an illustrative PMD and OSCC
prevalence of 2.0%.
We did not recover any studies on the DTA of vital
staining, autofluorescence and tissue reflectance, cyto-
logic testing and vital staining, and tissue reflectance
adjuncts. Therefore, we could not include any for the
evaluation of seemingly innocuous lesions in the oral
cavity.
Evidence on the use of adjuncts in patients
with clinically evident lesions suspected to be
potentially malignant or malignant. We identified
44 studies27,28,30,32-38,40-68,70-74 in which the investigators
addressed the DTA of autofluorescence, cytologic testing,
vital staining, tissue reflectance, cytologic testing and vital
staining, and tissue reflectance and vital staining.
eTable 324-70 summarizes the characteristics of the
included populations. Investigators conducted all studies
in a secondary or tertiary setting with the exception
of Rahman and colleagues42. Pooled sensitivity and spec-
ificity of adjuncts ranged from 0.31 to 0.95 for the evalua-
tion of these type of lesions.
TABLE 4
Autofluorscence adjuncts to evaluate clinically evident suspicious lesions.*
TEST RESULT DOWNSTREAM CONSEQUENCES EFFECT PER 100,000 PATIENTS TESTED (95%
CONFIDENCE INTERVAL [CI])
NUMBER
OF
LESIONS
(STUDIES)
QUALITY
OF THE
EVIDENCE
(GRADE)§Prevalence 0.25%
† Prevalence 2%‡
True Positives
(Patients With Need
for Biopsy)
Patients will be correctly identified as
having a potentially malignant or
malignant disorder and a timely referral
to a specialist or biopsy will be carried
out.
225 (190 to 250) 1,800 (1,520 to 2,000)
616 (7) Low¶,#,**
False Negatives
(Patients Incorrectly
Classified as Not
Having Need for
Biopsy)
Appropriate diagnostic would be missed,
worsening the prognosis of the disease.
25 (0 to 610) 200 (0 to 480)
True Negatives
(Patients Without
Need for Biopsy)
Patients will receive reassurance that
they do not have a potentially malignant
or malignant disorder.
71,820 (34,913 to 99,750) 70,560 (34,300 to 98,000)
616 (7) Low¶,#,**False Positives
(Patients Incorrectly
Classified as Having
Need for Biopsy)
Patients would be incorrectly identified
as having a potentially malignant or
malignant disorder and would undergo
additional unnecessary testing and
biopsy.
27,930 (0 to 64,837) 27,440 (0 to 63,700)
* Setting: Primary care. Pooled sensitivity, 0.90 (95% confidence interval [CI], 0.76 to 1.00). Pooled specificity, 0.72 (95% CI, 0.35 to 1.00). Positive
likelihood ratio, 3.17 (95% CI, 0.85 to 11.80). Negative likelihood ratio, 0.14; (95% CI, 0.03 to 0.64). Sources: Awan and colleagues,24 Farah and
colleagues,25 Hanken and colleagues,26 Koch and colleagues,27 Onizawa and colleagues,29 Petruzzi and colleagues,30 and Scheer and colleagues.31
† We estimated the prevalence by using data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program (300,682
people living with oral cavity and pharynx cancer in the United States in 2013) and the 2010 census data for adults 45 years or older collected by the
US Census Bureau.
‡ The panel provided illustrative prevalence as an estimation of the number of histopathologic diagnoses from dysplasia to cancer.
§ GRADE: Grading of Recommendations Assessment, Development and Evaluation.
¶ Patient selection and exclusion from analysis were inappropriate. Poor-quality reporting did not provide sufficient information to judge key risk of
bias domains.
# The investigators conducted most studies in secondary and tertiary care settings. Most patients had a higher probability of having a malignant or
potentially malignant disorder.
** The positivity threshold for the reference test included from mild dysplasia to cancer in all studies except for that of Awan and colleagues24 and
Farah and colleagues.25
ORIGINAL CONTRIBUTIONSAutofluorescence. Seven studies informed this com-
parison with the investigators evaluating data from 616
lesions.24-27,29-31 The positivity threshold for the criterion
standard included from mild dysplasia to OSCC, except
for the study by Farah and colleagues,25 in which we were
unable to elucidate how the authors classified a positive
test result.
When a clinician uses autofluorescence, 90% of
lesions with the target condition will be identified
correctly as positive by using the adjunct (sensitivity,
0.90; 95% CI, 0.76 to 1.00). However, 72% of lesions
without the target condition will be identified
correctly as negative by using the adjunct (specificity,
0.72; 95% CI, 0.35 to 1.00) (eFigures 624-27,29-31 and 7,
available online at the end of this article). See
Table 4,24-27,29-31 which includes additional absolute
measures calculated using an illustrative PMD and
OSCC prevalence of 2.0%.
Cytologic testing. Fifteen studies informed this com-
parison with the investigators evaluating data from 2,148
lesions.32-35,37-47 The positivity threshold for the criterion
standard included from mild dysplasia to OSCC in most
of the studies (eTable 10,24-70 available online at the endof this article). It was unclear how dysplasia was classified
in the study by Navone and colleagues,39 and Rahman
and colleagues42 classified mild dysplasia as negative for
the target condition.
When a clinician uses cytologic testing, 92% of lesions
with the target condition will be identified correctly as
positive by using the adjunct (sensitivity, 0.92; 95% CI,
0.86 to 0.98). However, 94% of lesions without the target
condition will be identified correctly as negative by using
the adjunct (specificity, 0.94; 95% CI, 0.88 to 0.99)
(eFigures 832-35,37-47 and 9, available online at the end of
this article). See Table 5,32-35,37-47 which includes addi-
tional absolute measures calculated using an illustrative
PMD and OSCC prevalence of 2.0%.
Vital staining. Fifteen studies informed this
comparison with the investigators evaluating data from
1,453 lesions.42,48-61 The positivity threshold for the
criterion standard included from mild dysplasia to OSCC
in all studies except for those of Rahman and col-
leagues,42 Singh and Shukla,61 and Cheng and Yang,53
(eTable 10,24-70 available online at the end of this article).
Rahman and colleagues42 classified mild dysplasia as
negative, and Singh and Shukla61 considered all dysplasiaJADA 148(11) http://jada.ada.org November 2017 805
TABLE 5
Cytologic adjuncts to evaluate clinically evident suspicious lesions.*
TEST RESULT DOWNSTREAM CONSEQUENCES EFFECT PER 100,000 PATIENTS TESTED (95%
CONFIDENCE INTERVAL [CI])
NUMBER
OF
LESIONS
(STUDIES)
QUALITY
OF THE
EVIDENCE
(GRADE)§Prevalence 0.25%
† Prevalence 2%‡
True Positives
(Patients With Need
for Biopsy)
Patients will be correctly identified as
having a potentially malignant or
malignant, and timely referral to a
specialist or biopsy will be performed.
230 (215 to 245) 1,840 (1,720 to 1,960)
2,148 (15) Low¶,#,**False Negatives
(Patients Incorrectly
Classified as Not
Having Need for
Biopsy)
Appropriate diagnostic would be
missed, worsening the prognosis of the
disease.
20 (5 to 35) 160 (40 to 280)
True Negatives
(Patients Without
Need for Biopsy)
Patients will receive reassurance that
they do not have a potentially malignant
or malignant disorder.
93,765 (87,780 to 98,753) 92,120 (86,240 to 97,020)
2,148 (15) Low¶,#,**False Positives
(Patients Incorrectly
Classified as Having
Need for Biopsy)
Patients would be incorrectly identified
as having a potentially malignant or
malignant disorder and would undergo
additional unnecessary testing and
biopsy.
5,985 (997 to 11,970) 5,880 (980 to 11,760)
* Setting: primary care. Pooled sensitivity, 0.92 (95% confidence interval [CI], 0.86 to 0.98). Pooled specificity, 0.94 (95% CI, 0.88 to 0.99). Positive
likelihood ratio, 14.18 (95% CI, 5.82 to 34.59). Negative likelihood ratio, 0.08 (95% CI, 0.04 to 0.18). Sources: Delavarian and colleagues,32 Fontes
and colleagues,33 Kammerer and colleagues,34 Koch and colleagues,35 Mehrotra and colleagues,37 Nanayakkara and colleagues,38 Navone and col-
leagues,40 Navone and colleagues,39 Ng and colleagues,41 Rahman and colleagues,42 Scheifele and colleagues,43 Sciubba,44 Seijas-Naya and col-
leagues,45 Svirsky and colleagues,46 and Trakroo and colleagues.47
† We estimated the prevalence by using data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program (300,682
people living with oral cavity and pharynx cancer in the United States in 2013) and the 2010 census data for adults 45 years or older collected by the
US Census Bureau.
‡ The panel provided illustrative prevalence as an estimation of the number of histopathologic diagnoses from dysplasia to cancer.
§ GRADE: Grading of Recommendations Assessment, Development and Evaluation.
¶ Patient selection and exclusion from analysis were inappropriate, index and reference tests were conducted in an unblinded fashion, and in some
cases the time between index and reference test was greater than 2 weeks. It was unclear whether all participants received the reference test.
Poorquality reporting did not provide sufficient information to judge key risk of bias domains.
# Investigators conducted most studies in secondary and tertiary care settings. Most patients had a higher probability of having a malignant or
potentially malignant disorder.
** The positivity threshold for the reference test included from mild dysplasia to cancer in all studies except for those of Kammerer and colleagues,34
Navone and colleagues,39 and Rahman and colleagues.42 The positivity threshold included atypia for Rahman and colleagues,42 Scheifele and
colleagues43 (10/96), Sciubba (52/298), and Svirsky and colleagues.46 Parentheses indicate the number of atypical results out of the total (atypical
þ positive results).
ORIGINAL CONTRIBUTIONSnegative. It was unclear how Cheng and Yang53 classified
the varying grades of dysplasia.
When a clinician uses vital staining, 87% of lesions
with the target condition will be identified correctly as
positive by using the adjunct (sensitivity, 0.87; 95% CI,
0.80 to 0.94). However, 71% of lesions without the target
condition will be identified correctly as negative by using
the adjunct (specificity, 0.71; 95% CI, 0.61 to 0.82)
(eFigures 1042,48-61 and 11, available online at the end of
this article). See Table 6,42,48-61 which includes additional
absolute measures calculated using an illustrative PMD
and OSCC prevalence of 2.0%.
Tissue reflectance. Five studies informed this com-
parison with the investigators evaluating data from 390
lesions.62-66 The positivity threshold for the criterion
standard included from mild dysplasia to OSCC in all
studies with the exception of those of Chainani-Wu and
colleagues,62 Ujaoney and colleagues,65 and Farah and
McCullough63(eTable 10,24-70 available online at the end
of this article). Ujaoney and colleagues65 classified mild806 JADA 148(11) http://jada.ada.org November 2017dysplasia as negative, and Chainani-Wu and colleagues62
classified mild and moderate dysplasia as negative. It
was unclear how Farah and McCullough63 classified
dysplasia.
When a clinician uses tissue reflectance, 72% of
lesions with the target condition will be identified
correctly as positive by using the adjunct (sensitivity,
0.72; 95% CI, 0.62 to 0.81). However, 31% of lesions
without the target condition will be identified
correctly as negative by using the adjunct (specificity,
0.31; 95% CI, 0.25 to 0.36) (eFigures 1262-66 and 13,
available online at the end of this article). See
Table 7,62-66 which includes additional absolute mea-
sures calculated using an illustrative PMD and OSCC
prevalence of 2.0%.
Cytologic testing and vital staining. Two studies
informed this comparison with the investigators eval-
uating data from 139 lesions.69,70 The positivity
threshold for the criterion standard included from
mild dysplasia to OSCC in Gupta and colleagues,70 but
TABLE 6
Vital staining adjuncts to evaluate clinically evident suspicious lesions.*
TEST RESULT DOWNSTREAM CONSEQUENCES EFFECT PER 100,000 PATIENTS TESTED
(95% CONFIDENCE INTERVAL [CI])
NUMBER
OF
LESIONS
(STUDIES)
QUALITY
OF THE
EVIDENCE
(GRADE)§Prevalence 0.25%
† Prevalence 2%‡
True Positives
(Patients With Need
for Biopsy)
Patients will be correctly identified as
having a potentially malignant or
malignant disorder and a timely referral
to a specialist or biopsy will be carried
out.
217 (200 to 235) 1,740 (1,600 to 1,880)
1,453 (15) Low¶,#,**
False Negatives
(Patients Incorrectly
Classified as Not
Having Need for
Biopsy)
Appropriate diagnostic would be
missed, worsening the prognosis of the
disease.
33 (15 to 50) 260 (120 to 400)
True Negatives
(Patients Without
Need for Biopsy)
Patients will receive reassurance that
they do not have a potentially malignant
or malignant disorder.
70,823 (60,848 to 81,795) 69,580 (59,780 to 80,360)
1,453 (15) Low¶,#,**False Positives
(Patients Incorrectly
Classified as Having
Need for Biopsy)
Patients would be incorrectly identified
as having a potentially malignant or
malignant disorder and would undergo
additional unnecessary testing and
biopsy.
28,927 (17,955 to 38,902) 28,420 (17,640 to 38,220)
* Setting: primary care. Pooled sensitivity, 0.87 (95% confidence interval [CI], 0.80 to 0.94). Pooled specificity, 0.71 (95% CI, 0.61 to 0.82). Positive
likelihood ratio, 3.04 (95% CI, 2.06 to 4.48). Negative likelihood ratio, 0.18 (95% CI, 0.10 to 0.32). Sources: Allegra and colleagues,48 Awan and
colleagues,49 Cancela-Rodriguez and colleagues,50 Chaudhari and colleagues,51 Chen and colleagues,52 Cheng and Yang,53 Du and colleagues,54
Mashberg,55 Nagaraju and colleagues,56 Onofre and colleagues,57 Rahman and colleagues,42 Silverman and colleagues,58 Singh and Shukla,61
Upadhyay and colleagues,59 and Warnakulasuriya and Johnson.60
† We estimated the prevalence by using data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program (300,682
people living with oral cavity and pharynx cancer in the United States in 2013) and the 2010 census data for adults 45 years or older collected by the
US Census Bureau.
‡ The panel provided illustrative prevalence as an estimation of the number of histopathologic diagnoses from dysplasia to cancer.
§ GRADE: Grading of Recommendations Assessment, Development and Evaluation.
¶ Patient selection and exclusion from analysis were inappropriate. It was unclear whether all participants received the reference test. Poor-quality
reporting did not provide sufficient information to judge key risk of bias domains.
# Investigators conducted most studies in secondary and tertiary care settings. Most patients had a higher probability of having a malignant or
potentially malignant disorder.
** The positivity threshold for the reference test included from mild dysplasia to cancer in all studies except for those of Cheng and Yang,53 Rahman
and colleagues,42 and Singh and Shukla.61
ORIGINAL CONTRIBUTIONSGuneri and colleagues69 classified only severe dysplasia
as positive (eTable 10,24-70 available online at the end
of this article).
When a clinician uses cytologic testing and vital
staining, 95% of lesions with the target condition will be
identified correctly as positive by using the adjunct
(sensitivity, 0.95; 95% CI, 0.86 to 0.99). However, 68% of
lesions without the target condition will be identified
correctly as negative by using the adjunct (specificity,
0.68; 95% CI, 0.56 to 0.78) (eFigures 1469,70 and 15,
available online at the end of this article). See Table 8,69,70
which includes additional absolute measures calculated
using an illustrative PMD and OSCC prevalence of 2.0%.
Tissue reflectance and vital staining. Four studies
informed this comparison with the investigators eval-
uating data from 307 lesions.62,65,67,68 The positivity
threshold for the criterion standard included from mild
dysplasia to OSCC in all studies with the exception of
those of Ujaoney and colleagues65 and Chainani-Wu
and colleagues.62 Ujaoney and colleagues65 classified
mild dysplasia as negative, and Chainani-Wu and col-
leagues62 classified mild and moderate dysplasia asnegative (eTable 10,24-70 available online at the end of
this article).
When a clinician uses tissue reflectance and vital
staining, 81% of lesions with the target condition will be
identified correctly as positive by using the adjunct
(sensitivity, 0.81; 95% CI, 0.71 to 0.89). However, 69% of
lesions without the target condition will be identified
correctly as negative by using the adjunct (specificity,
0.69; 95% CI, 0.63 to 0.75) (eFigures 1662,65,67,68 and
17, available online at the end of this article). See
Table 9,62-68 which includes additional absolute mea-
sures calculated using an illustrative PMD and OSCC
prevalence of 2.0%.
Sensitivity analyses. eTables 11 through 1432-35,37-61,69
and Appendix 2 (available online at the end of this
article) provide information about the sensitivity
analyses.
DISCUSSION
Summary of main results. We planned this review
and analysis assuming that all commercially available
adjuncts may have the potential to assist primary careJADA 148(11) http://jada.ada.org November 2017 807
TABLE 7
Tissue reflectance adjuncts to evaluate clinically evident suspicious lesions.*
TEST RESULT DOWNSTREAM CONSEQUENCES EFFECT PER 100,000 PATIENTS TESTED
(95% CONFIDENCE INTERVAL [CI])
NUMBER
OF
LESIONS
(STUDIES)
QUALITY
OF THE
EVIDENCE
(GRADE)§Prevalence 0.25%
† Prevalence 2%‡
True Positives
(Patients With Need
for Biopsy)
Patients will be correctly identified as
having a potentially malignant or
malignant disorder and a timely referral
to a specialist or biopsy will be carried
out.
180 (155 to 203) 1,440 (1,240 to 1,620)
390 (5) Low¶,#,**
False Negatives
(Patients Incorrectly
Classified as Not
Having Need for
Biopsy)
Appropriate diagnostic would be missed,
worsening the prognosis of the disease.
70 (47 to 95) 560 (380 to 760)
True Negatives
(Patients Without
Need for Biopsy)
Patients will receive reassurance that
they do not have a potentially malignant
or malignant disorder.
30,923 (24,938 to 35,910) 30,380 (24,500 to 35,280)
390 (5) Low¶,#,**False Positives
(Patients Incorrectly
Classified as Having
Need for Biopsy)
Patients would be incorrectly identified
as having a potentially malignant or
malignant disorder and would undergo
additional unnecessary testing and
biopsy.
68,827 (63,840 to 74,812) 67,620 (62,720 to 73,500)
* Setting: primary care. Pooled sensitivity, 0.72 (95% confidence interval [CI], 0.62 to 0.81). Pooled specificity, 0.31 (95% CI, 0.25 to 0.36). Positive
likelihood ratio, 1.04 (95% CI, 0.90 to 1.20). Negative likelihood ratio, 0.91 (95% CI, 0.63 to 1.30). Sources: Awan and colleagues,66 Chainani-Wu
and colleagues,62 Farah and McCullough,63 McIntosh and colleagues,64 and Ujaoney and colleagues.65
† We estimated the prevalence by using data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program (300,682
people living with oral cavity and pharynx cancer in the United States in 2013) and the 2010 census data for adults 45 years or older collected by the
US Census Bureau.
‡ The panel provided illustrative prevalence as an estimation of the number of histopathologic diagnoses from dysplasia to cancer.
§ GRADE: Grading of Recommendations Assessment, Development and Evaluation.
¶ Only 1 of 4 studies had a low risk of bias. Poor-quality reporting did not provide sufficient information to judge key risk of bias domains.
# Investigators conducted all studies in secondary and tertiary care settings. Most patients had a higher probability of having a malignant or potentially
malignant disorder.
** The positivity threshold for the reference test included from mild dysplasia to cancer in all studies except for those of Chainani-Wu and colleagues,62
Farah and McCullough,63 and Ujaoney and colleagues.65
ORIGINAL CONTRIBUTIONSclinicians in evaluating a patient’s need for referral to a
specialist or need for biopsy of lesions that exhibit
varying degrees of suspiciousness of malignancy
(eFigures 18-21). Many of these adjuncts are marketed
heavily for their potential usefulness in early detection of
target conditions in patients with and without clinically
evident lesions.
In primary care, the prevalence of PMDs and OSCC is
low (approximately between 0.25% to 2.0% on the basis
of our estimation).81,82 This low prevalence means that
clinicians’ main role in such settings would be ruling out
the presence of target conditions, distinguishing seem-
ingly innocuous lesions that are likely reactive or in-
flammatory in nature (most of them) from those that
require further testing, including biopsy or referral.
However, for clinicians in secondary and tertiary care
settings (specialists), the main goal is actually the
opposite: ruling in the presence of a target condition.
One desirable characteristic of an adjunct intended to be
used in a primary care setting is having a high sensitivity
to minimize the proportion of false-negative results to
avoid missing patients requiring biopsy or referral—in
other words, avoiding sending patients home with a
negative result and, therefore, the assumption that no808 JADA 148(11) http://jada.ada.org November 2017biopsy or referral is needed when, in reality, they actually
have a PMD or OSCC. The other desirable characteris-
tics of an adjunct intended to be used in a primary care
setting are being inexpensive and being minimally
invasive.
According to our analysis, if a clinician uses cytologic
testing to identify the target condition in a group of
100,000 people with clinically evident lesions (of whom
250 truly have the target condition), 20 of them would
be classified incorrectly as not needing biopsy (false-
negative result), and 5,985 people would be identified
incorrectly as needing biopsy or referral (false-positive
result). If vital staining were used, 33 people would be
classified incorrectly as not needing biopsy, and 28,927
would be identified incorrectly as needing biopsy or
referral. If an autofluorescence method were used, 25
people would be classified incorrectly as not needing
biopsy, and 27,930 would be identified incorrectly as
needing biopsy or referral. Finally, if tissue reflectance
adjuncts were used, 70 people would be classified
incorrectly as not needing biopsy, and 68,827 would be
identified incorrectly as needing biopsy or referral.
Therefore, all included adjuncts (cytologic testing, auto-
fluorescence, tissue reflectance, and vital staining) would
TABLE 8
Cytologic testing and vital staining adjuncts to evaluate clinically evident
suspicious lesions.*
TEST RESULT DOWNSTREAM CONSEQUENCES EFFECT PER 100,000 PATIENTS TESTED
(95% CONFIDENCE INTERVAL [CI])
NUMBER
OF
LESIONS
(STUDIES)
QUALITY
OF THE
EVIDENCE
(GRADE)§Prevalence 0.25%
† Prevalence 2%‡
True Positives
(Patients With Need
for Biopsy)
Patients will be correctly identified as
having a potentially malignant or
malignant disorder and a timely referral
to a specialist or biopsy will be carried
out.
238 (215 to 248) 1,900 (1,720 to 1,980)
139 (2) Verylow¶,#,**,††False Negatives
(Patients Incorrectly
Classified as Not
Having Need for
Biopsy)
Appropriate diagnostic would be missed,
worsening the prognosis of the disease.
12 (2 to 35) 100 (20 to 280)
True Negatives
(Patients Without
Need for Biopsy)
Patients will receive reassurance that
they do not have a potentially malignant
or malignant disorder.
67,830 (55,860 to 77,805) 66,640 (54,880 to 76,440)
139 (2) Verylow¶,#,**,††
False Positives
(Patients Incorrectly
Classified as Having
Need for Biopsy)
Patients would be incorrectly identified
as having a potentially malignant or
malignant disorder and would undergo
additional unnecessary testing and
biopsy.
31,920 (21,945 to 43,890) 31,360 (21,560 to 43,120)
* Setting: primary care. Pooled sensitivity, 0.95 (95% confidence interval [CI], 0.86 to 0.99). Pooled specificity, 0.68 (95% CI, 0.56 to 0.78). Positive
likelihood ratio, 2.97 (95% CI, 2.14 to 4.12). Negative likelihood ratio, 0.07 (95% CI, 0.02 to 0.22). Sources: Guneri and colleagues69 and Gupta and
colleagues.70
† We estimated the prevalence by using data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program (300,682
people living with oral cavity and pharynx cancer in the United States in 2013) and the 2010 census data for adults 45 years or older collected by the
US Census Bureau.
‡ The panel provided illustrative prevalence as an estimation of the number of histopathologic diagnoses from dysplasia to cancer.
§ GRADE: Grading of Recommendations Assessment, Development and Evaluation.
¶ Poor-quality reporting prevented us from assessing risk of bias for key domains.
# Investigators conducted all studies in secondary and tertiary care settings. Most patients had a higher probability of having a malignant or potentially
malignant disorder.
** There was a small sample size of only 139 lesions.
†† The positivity threshold for the reference test included from mild dysplasia to cancer in addition to atypical results in the study of Guneri and
colleagues69 but not in that of Gupta and colleagues.70
ORIGINAL CONTRIBUTIONSresult in more false-positive than true-positive results if
used in primary care settings. All of these findings were
supported by low-quality to very low-quality evidence.
Of all adjuncts being assessed, cytologic testing seems to
have the highest accuracy.
Quality of the evidence. Although we were interested
in the use of adjuncts in primary care settings, most of
the included studies were conducted in secondary and
tertiary care settings such as hospitals or specialty clinics.
Furthermore, though all adjuncts assessed are commer-
cially available in the United States, most of the included
studies were conducted in other countries. The relative
skills of practitioners, assessment of outcomes, and
positivity thresholds for both adjuncts and criterion
standards were notably diverse. The assessment of the
quality of evidence ranged from low to very low for most
outcomes, where the main issues to reduce our confi-
dence were limitations in study design and indirectness.
Comparison with Cochrane reviews used for the
update and other non-cochrane systematic review
results. For a description of the differences introduced inthis review compared with the 2 preexisting Cochrane
reviews informing this work, see Appendix 2 (available
online at the end of this article).
Strengths and limitations of this review. Strengths
of this review include the rigor of the methodology,
including screening of potentially eligible studies and
data extraction being conducted in duplicate and
independently by 2 reviewers; the use of preexisting,
high-quality systematic reviews allowing us to elaborate
on a fruitful collaboration (methodology, data analysis,
and sharing of data) with the Cochrane Oral Health
Group; the use of DTA pooled estimates; the use of the
GRADE approach to determine our certainty in the
evidence; and the use of a sensitivity analysis to
determine the robustness of results from primary
studies with issues of verification bias. This review also
has its limitations. Although the most informative evi-
dence about the benefits and harms of using adjuncts in
the clinical workup for PMDs and OSCC should come
from patient-important outcomes, we were unable to
find this type of data. Instead, we were able only toJADA 148(11) http://jada.ada.org November 2017 809
TABLE 9
Tissue reflectance and vital staining adjuncts to evaluate clinically evident
suspicious lesions.*
TEST RESULT DOWNSTREAM CONSEQUENCES EFFECT PER 100,000 PATIENTS TESTED
(95% CONFIDENCE INTERVAL [CI])
NUMBER
OF
LESIONS
(STUDIES)
QUALITY
OF THE
EVIDENCE
(GRADE)§Prevalence 0.25%
† Prevalence 2%‡
True Positives
(Patients With Need
for Biopsy)
Patients will be correctly identified as
having a potentially malignant lesion,
and timely referral to a specialist or
biopsy will be performed.
203 (178 to 223) 1,620 (1,420 to 1,780)
307 (4) Low¶,#,**False Negatives
(Patients Incorrectly
Classified as Not
Having Need for
Biopsy)
Appropriate diagnostic would be missed,
worsening the prognosis of the disease.
47 (27 to 72) 380 (220 to 580)
True Negatives
(Patients Without
Need for Biopsy)
Patients will receive reassurance that
they do not have a potentially malignant
or malignant disorder.
68,828 (62,843 to 74,813) 67,620 (61,740 to 73,500)
307 (4) Low¶,#,**False Positives
(Patients Incorrectly
Classified as Having
Need for Biopsy)
Patients would be incorrectly identified
as having a potentially malignant or
malignant disorder and would undergo
additional unnecessary testing and
biopsy.
30,922 (24,937 to 36,907) 30,380 (24,500 to 36,260)
* Setting: primary care. Pooled sensitivity, 0.81 (95% confidence interval [CI], 0.71 to 0.89). Pooled specificity, 0.69 (95% CI, 0.63 to 0.75). Positive
likelihood ratio, 2.62 (95% CI, 2.10 to 3.27). Negative likelihood ratio, 0.27 (95% CI, 0.17 to 0.44). Sources: Chainani-Wu and colleagues,62
Epstein and colleagues,67 Mojsa and colleagues,68 and Ujaoney and colleagues.65
† We estimated the prevalence by using data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program (300,682
people living with oral cavity and pharynx cancer in the United States in 2013) and the 2010 census data for adults 45 years or older collected by the
US Census Bureau.
‡ The panel provided illustrative prevalence as an estimation of the number of histopathologic diagnoses from dysplasia to cancer.
§ GRADE: Grading of Recommendations Assessment, Development and Evaluation.
¶ Three of 4 studies showed high risk of bias in patient selection and the application of the index test.
# Investigators conducted all studies in secondary care settings. Most patients had a higher probability of having a malignant or potentially malignant
disorder.
** The positivity threshold for the reference test included from mild dysplasia to cancer in all studies except for those of Chainani-Wu and colleagues62
and Ujaoney and colleagues.65
ORIGINAL CONTRIBUTIONSsummarize DTA estimates and illustrative downstream
consequences. A second limitation is that we identified
only studies conducted in secondary and tertiary care
settings, whereas the original clinical questions referred
to the use of these adjuncts in primary care, intro-
ducing issues of indirectness where the generalizability
of the results is limited because the populations, ad-
juncts, and outcomes of interest differ from those
available in the literature. Finally, most outcomes were
affected by issues of risk of bias.
CONCLUSIONS
Overall, adjuncts showed limited DTA when contextu-
alized to be used in primary care settings. The main
concerns are the high rate of false-positive results and
serious issues of risk of bias and indirectness of the
evidence. Low-quality evidence suggests that cytologic
testing seems to be the most accurate adjunct among
those included in this review. Biopsy and histopathologic
assessment remain the single definitive test to diagnose
PMDs and OSCC through detecting dysplasia. In rela-
tion to PVPs, anxiety and denial seem to be key barriers
to diagnosis and initiating treatment. Clinicians should810 JADA 148(11) http://jada.ada.org November 2017remain skeptical about the potential benefit that these
devices may offer in practice. n
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METHODS
Data extraction. Two reviewers (M.P.T. and O.U.)
independently and working in duplicate used a stan-
dardized form (Excel, Microsoft) to extract the data.
They recorded the following data from each study: au-
thor’s last name and year of publication, country, setting
(primary, secondary, or tertiary care), population char-
acteristics (age, sex, selection criteria, and clinical diag-
nosis of evident lesions), the number of patients included
in the study, the number of lesions included in the
analysis, index test and criterion standard characteristics,
positivity thresholds, source of funding, financial and
intellectual conflicts of interest, and diagnostic test ac-
curacy (DTA) and patient-important outcomes. A third
reviewer (A.C.L.), who acted as arbiter, clarified any
discrepancies between extractors. We made efforts to
contact primary study authors whenever deemed
necessary.
Assessment of heterogeneity. For the pooled esti-
mates of DTA studies, we visually assessed heterogeneity
by using as a reference how close the sensitivity and
specificity estimates were among studies, as well as the
extension of overlap of their 95% confidence intervals.
We performed this assessment in accordance with
guidance from the Cochrane Handbook for Diagnostic
Test Accuracy Reviews.13
Assessment of publication bias. We did not assess
publication bias as recommended by the Cochrane
Handbook. Heterogeneity in test accuracy is prevalent
in most reviews of DTA, and interpreting statistical
evidence of funnel plot asymmetry could be
misleading.87,88
Sensitivity analysis. In anticipation of eventual issues
such as risk of bias, specifically verification bias (for
example, we did not keep index test and criterion stan-
dard patient populations or when different types of le-
sions were tested consistent), we conducted sensitivity
analysis to examine to what extent these study differ-
ences meaningfully changed summary measures. We
compared the pooled estimates for sensitivity and spec-
ificity and their 95% confidence intervals, including and
excluding such types of studies.
RESULTS
PVPs studies. Investigators conducted the primary
studies in Australia,72 the United Kingdom,73,75,79,80 the
United States,74 Jordan,76 Canada,77 and Germany.78
In all primary studies, the investigators used a cross-
sectional study design and telephone interviews and self-
reported and closed-ended questionnaires as a means of
collecting data. Three main topics emerged from the
analysis. First, fear and anxiety are identified as
some of the most important barriers for seeking care.
Investigators in 2 studies reported that delaying813.e1 JADA 148(11) http://jada.ada.org November 2017consultation of a primary care practitioner for initial
evaluation or attending a specialty clinic after referral can
range between 1 and 3 months.72,80 Rogers and col-
leagues79 found that one-third of all participants treated
for oropharyngeal and oral squamous cell carcinoma
(OSCC) known to be alive by the time of data collection
mentioned that they did not share the finding of having a
potentially malignant disorder (PMD) or OSCC with
anyone during the initial evaluations.71 Second, the
acceptability of conducting a clinical examination to
identify PMDs was high among participants.71,76 Third,
participants highlighted the interest of being educated
about ways to reduce their risk of having oral cancer and
suggested that media coverage could be an effective way
to increase awareness about the early manifestation of
PMDs and OSCC (eTable 5,71-80 available online at the
end of this article).
Risk of bias of included reviews. Using the Assessing
the Methodological Quality of Systematic Reviews tool,
we determined that both Cochrane reviews had the
highest methodological quality that a study can have ac-
cording to this tool. The reviews summarizing the evi-
dence of salivary adjuncts for the early diagnosis of OSCC
were evaluated as being of high23 and moderate22 quality.
The 2 Cochrane reviews needed to be updated, but the
reviews on salivary adjuncts did not (eTables 6-9,4,5,16,23,24
available online at the end of this article).
Sensitivity analysis. To evaluate the impact of veri-
fication bias from the studies contributing to the DTA
pooled estimates, we pooled data for studies with and
without verification bias separately. Four studies were
affected by verification bias, and these studies informed 2
comparisons (vital staining and cytologic testing).39,45,46,51
For either comparison listed, the DTA pooled estimates
seemed to show similar results (eTables 11-14,32-35,37-61,69
available online at the end of this article).DISCUSSION
This systematic review is an update of the 2013 and the
2015 Cochrane reviews,5,85 but there are a few key
methodological differences. First, the 2015 Cochrane re-
view included lichen planus, actinic keratosis, hereditary
disorders (no studies found), and cancers of the lip
(no studies of lip cancers found) as relevant target con-
ditions that this update did not, and we included
erythroleukoplakia as a relevant target condition, which
was not included explicitly in the Cochrane review.
Second, for the risk of bias assessment, the authors of the
2015 Cochrane review used a modified version of
QUADAS-2, whereas we used a comparable version
provided in Review Manager, Version 5.3.4,5 We reas-
sessed all Cochrane risk of bias judgments during the
update for the sake of consistency. Third, we needed to
remove a few adjuncts that were not available in the US
market, which was 1 of our inclusion criteria. Fourth, we
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ORIGINAL CONTRIBUTIONSregrouped the comparisons, splitting the light-based
category into its 2 subcategories: autofluorescence and
tissue reflectance adjuncts. Fifth, we made efforts to
obtain the most accurate and current estimate of the
prevalence of PMDs and OSCC in the United States and
used it in our analysis. We did not use the estimate
calculated for the 2015 Cochrane review.
Investigators in 4 systematic reviews summarized the
evidence on the use of devices to assist the diagnostic
process for PMDs and OSCC, and their findings are in
agreement with ours. Nagi and colleagues83 and Awan
and Patil84 evaluated the clinical usefulness of auto-
fluorescence adjuncts. The investigators in these reviews
found that sensitivity and specificity for autofluorescence
devices ranged from 22% to 100% and from 16% to 100%,
respectively. They concluded that this type of adjunct
might be helpful for the experienced clinicians in a sec-
ondary or tertiary care setting, where the prevalence is
high, but of little help in primary care settings, particu-
larly because of the inability of autofluorescence methods
to help differentiate dysplasia from benign reactive or
inflammatory lesions or nondysplasia. Carreras-Torras
and Gay-Escoda85 were unable to find evidence to sup-
port any diagnostic technique for the purpose of
replacing biopsy. In addition, they described that the
evidence to support the use of adjuncts in practice is
limited. Rashid and Warnakulasuriya86 also found vari-
able results across autofluorescence and chem-
iluminiscence adjuncts. They concluded that the
available evidence suggests that these devices may be
better suited for clinicians in specialty care settings with
more clinical experience and with a higher prevalence of
the condition compared with that seen in primary care
settings.+ ? ? – + + +
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eFigure 10. Forest plot of vital staining for clinically evident, suspicious lesions. The thin horizontal lines indicate confidence interval (CI) magnitude.
FN: False negative. FP: False positive. TN: True negative. TP: True positive.
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eFigure 11. Summary receiver operating characteristic curve for vital staining for clinically evident, suspicious lesions. Open circles indicate the
individual sensitivity and specificity for each study and the filled circles indicate the pooled estimate for the particular adjunct in question.
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eFigure 12. Forest plot of tissue reflectance for clinically evident, suspicious lesions. The thin horizontal lines indicate confidence interval (CI)
magnitude. FN: False negative. FP: False positive. TN: True negative. TP: True positive.
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eFigure 13. Summary receiver operating characteristic curve for tissue reflectance for clinically evident, suspicious lesions. Open circles indicate the
individual sensitivity and specificity for each study and the filled circles indicate the pooled estimate for the particular adjunct in question.
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eFigure 14. Forest plot of cytology and vital staining for clinically evident, suspicious lesions. The thin horizontal lines indicate confidence interval (CI)
magnitude. FN: False negative. FP: False positive. TN: True negative. TP: True positive.
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eFigure 15. Summary receiver operating characteristic curve for cytology and vital staining for clinically evident, suspicious lesions. Open circles
indicate the individual sensitivity and specificity for each study and the filled circles indicate the pooled estimate for the particular adjunct in question.
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eFigure 16. Forest plot of tissue reflectance and vital staining for clinically evident, suspicious lesions. The thin horizontal lines indicate confidence
interval (CI) magnitude. FN: False negative. FP: False positive. TN: True negative. TP: True positive.
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eFigure 17. Summary receiver operating characteristic curve for tissue reflectance and vital staining for clinically evident, suspicious lesions.
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eFigure 18. No clinically evident lesion or other symptoms.
eFigure 20. Seemingly malignant lesion.
eFigure 19. Clinically evident, seemingly-innocuous or non-suspicious
lesion.
eFigure 21. Clinically evident suspicious lesion.
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Glossary of terms.
TERM DEFINITION
Target Condition A target condition is a disease or health outcome of interest.
Screening Versus Evaluation Screening is the process by which a practitioner surveys a patient without symptoms to determine whether he or
she is likely or unlikely to have a condition or disease. In mass screening programs, also known as community-
based screening or population-based screening, the target group is invited to participate specifically for the
purpose of detecting disease. In the dental care setting, the act of screening for oral cancer usually occurs when a
patient reports for routine care, a form of opportunistic screening. Evaluation generally involves a broader survey of
patients, both with and without symptoms, including a review of their medical, social, and dental history and a
physical assessment. In the dental care setting, this is accomplished through an intraoral and extraoral visual and
tactile examination to detect any tissue abnormalities, including potentially malignant and seemingly malignant
disorders.
CVTE* CVTE is the systematic visual inspection of the head and neck. This includes examination of the face, lips, and
mouth tissues under white light illumination for any signs or clinically detectable tissue abnormality or
morphologic change, such as changes in size, color, and texture. This is combined with regional palpation with
gloved fingers to detect changes in consistency and temperature of mucosa, skin, bone, joints, and lymph nodes.
Patient-reported symptoms could include globus sensation, unexplained ear pain or oropharyngeal pain,
hoarseness, and so on.
No Clinically Evident Lesions No clinically evident lesions or symptoms are the absence of any clinically detectable tissue abnormality or
symptoms during the CVTE of the dental patient.
Clinically Evident Lesions Clinically evident lesions are morphologically altered tissue noted at CVTE.
Clinically Evident, Seemingly
Innocuous, or Nonsuspicious
Lesions
Clinically evident, seemingly innocuous, or nonsuspicious lesions are areas of morphologically altered tissue noted
at examination for which the clinician considers a clinical diagnosis of a PMD† with features suggestive of dysplasia
or malignancy to be a remote possibility.
Clinically Evident, Suspicious
Lesions
Clinically evident, suspicious lesions are morphologically altered tissue noted at CVTE for which the clinician
considers a definitive diagnosis of a PMD (lesion with features suggestive of malignancy) or even a malignant
disorder to be a distinct possibility. These are likely to occur in the following anatomic sites: ventrolateral part of
the tongue, floor of mouth, and anterior tonsillar pillar and soft palate complex.
Seemingly Malignant Lesions Seemingly malignant lesions are a clinical diagnosis reserved for oral lesions with ominous clinical features
considered highly suggestive of malignancy.
PMDs‡ A target condition for this review, PMDs are identified through a clinical diagnosis and encompass oral mucosal
entities (lesions or disorders) that have an increased risk of the development of cancer.
PMDs can be diagnosed clinically as leukoplakia, erythroplakia, erythroleukoplakia, or submucous fibrosis, and
these lesions may occur among those with hereditary disorders with an increased risk of malignant transformation
and among heavy tobacco and alcohol users.
These diagnoses usually are assigned in a primary care setting through CVTE, through the presence of dysplasia
(that is, the only definitive indicator for potential malignancy or malignancy), and can be determined only through
biopsy and histopathologic assessment.
OSCC§ A target condition for this review, OSCC is the most common cancer of the oral cavity and is diagnosed after
histopathologic assessment of tissue obtained at biopsy. OSCC is a malignancy derived from the squamous
epithelium or oral mucosa.
Triage Test A triage test is used in an early stage of the diagnostic process to identify patients with a particular finding that will
be informative for subsequent steps in the testing pathway.
Adjuncts or Index Tests An adjunct is a test, device, technique, or technology marketed to assist primary care clinicians, possibly as a triage
test, in the detection of PMDs or seemingly malignant lesions for the assessment of their biological relevance.
Biopsy or Criterion Standard Biopsy followed by histopathologic assessment, a procedure used to detect dysplasia, is the criterion standard
diagnostic test for PMDs and OSCC. Biopsy can be either incisional or excisional. An incisional biopsy is a surgical
technique involving a scalpel or punch to sample a portion of a PMD for subsequent histopathologic examination
and a definitive diagnosis. An excisional biopsy is a surgical technique involving a scalpel or punch that removes all
clinically abnormal mucosa of a clinically evident lesion for subsequent histopathologic examination and a
definitive diagnosis.
Index Tests (Adjuncts) Versus
Criterion Standard (Biopsy)
An index test for a given lesion or condition is evaluated for diagnostic accuracy by comparison with a reference
standard or criterion standard diagnostic test.
True-Positive Test Result A true-positive test result indicates that an adjunct correctly helped identify a patient as having a PMD or malignant
disorder. A timely referral to a specialist or biopsy will be performed.
False-Positive Test Result A false-positive test result indicates that an adjunct incorrectly helped identify a patient as having a PMD or
malignant disorder. The patient would undergo additional unnecessary testing and biopsy.
True-Negative Test Result A true-negative test result indicates that an adjunct correctly helped identify a patient as not having a PMD or
malignant disorder. The patient will receive reassurance that he or she is healthy.
* CVTE: Conventional visual and tactile examination.
† PMD: Potentially malignant disorder.
‡ The literature indicates that there is no universal agreement on the definition and application of the term potentially malignant disorder (PMD), and
we attempted to reconcile inconsistencies as well as possible.
§ OSCC: Oral squamous cell carcinoma.
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TERM DEFINITION
False-Negative Test Result A false-negative test result indicates that an adjunct incorrectly helped identify a patient as not having a PMD or
malignant disorder. The appropriate diagnosis would be missed, worsening the prognosis of the disease.
Sensitivity Sensitivity is the ability of a test to help identify those with the disease correctly, also known as the true-positive
rate.
Specificity Specificity is the ability of a test to help identify those without the disease correctly, also known as the true-
negative rate.
Positive Likelihood Ratio A positive likelihood ratio indicates how much more likely a positive test result is in patients with the condition
versus in patients without the condition.
Negative Likelihood Ratio A negative likelihood ratio indicates the probability of a patient without the target condition having a negative test
result.
Pretest Probability Pretest probability is the proportion of people in the population at risk who have the disease at a specific time or
time interval (that is, the point prevalence or the period prevalence of the disease). In other words, it is the
probability, before the diagnostic test is performed, that a patient has the disease. Clinicians can estimate pretest
probabilities from routine data, practice data, or clinical judgment.
Posttest Probability Posttest probability is the proportion of patients testing positive who truly have the disease. It is similar to the
positive predictive value but apart from the test performance also includes a patient-based probability of having
disease.
Verification Bias Verification bias is a type of bias in which the results of an adjunct affect whether the criterion standard is used to
verify the test result.
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Levels of quality of evidence (certainty in the evidence).*
QUALITY LEVEL DEFINITION
High We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate We are moderately confident in the effect estimate: the true effect is likely to be close to the
estimate of the effect, but there is a possibility that it is substantially different.
Low Our confidence in the effect estimate is limited: the true effect may be substantially different
from the estimate of the effect.
Very Low We have very little confidence in the effect estimate: the true effect is likely to be substantially
different from the estimate of effect.
* Reproduced with permission of the publisher from Balshem and colleagues.21
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List of excluded studies.
REFERENCE REASON FOR EXCLUSION
1. Abt, E., DNA-image cytometry has promise for oral cancer
detection. Evidence-Based Dentistry, 2015. 16(4): p. 106-7.
Commentary
2. Afrogheh, A., et al., An evaluation of the Shandon Papspin liquid-
based oral test using a novel cytologic scoring system. Oral Surgery,
Oral Medicine, Oral Pathology and Oral Radiology, 2012. 113(6): p.
799-807.
Liquid-based cytologic testing, not commercially available
3. Agarwal, A., et al., Exploratory study to evaluate changes in
serum lipid levels as early diagnostic and/or prognostic indicators
for oral submucous fibrosis and cancer among gutkha consumers in
india. Asian Pacific Journal of Cancer Prevention: APJCP, 2015.
16(15): p. 6439-6444.
Case-control study and unclear application of a criterion standard
4. Aggarwal, S., S.C. Sharma, and S.N. Das, Galectin-1 and galectin-3:
plausible tumour markers for oral squamous cell carcinoma and
suitable targets for screening high-risk population. Clinica Chimica
Acta, 2015. 442: p. 13-21.
Oral squamous cell carcinoma cases were confirmed already
5. Agha-Hosseini, F. and I. Mirzaii-Dizgah, p53 as a neoplastic
biomarker in patients with erosive and plaque like forms of oral
lichen planus. Journal of Contemporary Dental Practice [Electronic
Resource], 2013. 14(1): p. 1-3.
No criterion standard
6. Agha-Hosseini, F., I. Mirzaii-Dizgah, and N.S. Miri-Zarandi, Unsti-
mulated salivary p53 in patients with oral lichen planus and squa-
mous cell carcinoma. Acta Medica Iranica, 2015. 53(7): p. 439-443.
Case-control study
7. Akhtar, K., et al., Transition of immunohistochemical expression
of E-cadherin and vimentin from premalignant to malignant lesions
of oral cavity and oropharynx. Oman Medical Journal, 2016. 31(3):
p. 165-169.
Prognosis, not diagnostic test study
8. Al-Omar, E., Future of optical biopsy in diagnosis of oral squamous
cell carcinoma (OSCC): A review and meta-analysis of relevant pub-
lished studies. Lasers in Surgery and Medicine, 2016. 48: p. 39-40.
Systematic review of optical biopsy
9. Alpaslan, C., et al., The role of direct fluorescence visualization for
screening of oral cancer in dental patients and its impact on raising
awareness. Oral Oncology, 2013. 49: p. S52.
Abstract only
10. Anderson, W.D., et al., Oral lesions you can’t afford to miss.
Journal of Family Practice, 2015. 64(7): p. 392-399.
Review of different lesion types
11. Andratschke, M., et al., Cytological and immunocytological
monitoring of oropharyngeal dysplasia and squamous cell carci-
nomas. Anticancer Research, 2015. 35(12): p. 6517-6520.
Oral squamous cell carcinoma cases were confirmed already
12. Anonymous, DenMat, LED dental’s VELscope Vx: saving lives by
detecting oral cancer early. Compendium of Continuing Education in
Dentistry, 2013. 34(1): p. 74.
News article about VELscope
13. Anonymous, U.S. Task Force unable to recommend for or against
oral cancer screenings by physicians. Journal of the California
Dental Association, 2014. 42(2): p. 86.
Review article
14. Aravindha Babu, N., et al., Salivary markers in cancer diagnosis—
A review. Research Journal of Pharmaceutical, Biological and
Chemical Sciences, 2014. 5(2): p. 1655-1658.
Review of salivary biomarkers
15. Bacci, C., et al., A comparison between histologic and clinical
diagnoses of oral lesions. Quintessence International, 2014. 45(9):
p. 789-94.
Comparison of histologic and clinical diagnosis; no mention of any
adjuncts of interest
16. Balasubramaniam, A.M., et al., Autofluorescence based diag-
nostic techniques for oral cancer. Journal of pharmacy and bioallied
sciences. 2015. 7(Suppl 2): p. S374-7.
Review of autofluorescence adjuncts
17. Bhatia, N., M.A. Matias, and C.S. Farah, Assessment of a decision
making protocol to improve the efficacy of VELscopeTM in general
dental practice: a prospective evaluation. Oral Oncology, 2014.
50(10): p. 1012-9.
Not all patients receiving VELscope examination received criterion
standard
18. Bhoopathi, V. and A.K. Mascarenhas, Utility of oral cancer
diagnostic adjuncts in the adult US populations. Journal of Oral
Pathology & Medicine, 2013. 42(5): p. 363-7.
Imputed oral cancer prevalence and oral cancer prevalence in high- and
low-risk groups. This article describes sensitivity analyses of experimenting
with different values for sensitivity and specificity.
* The authors of the 2015 Cochrane review4 included Sharwani 2006a, Sharwani 2006b, Remmerbach 2009, Leunig 2000, and Kulapaditharom 1998,
but we excluded them in this review.
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19. Bumb, D., et al., Oral visual examination for early detection of
potentially malignant mucosal disorders in an opportunistic popu-
lation. Oral Oncology, 2014. 50(1): p. e3-4.
Letter to the editor
20. Casparis, S., et al., Transepithelial brush biopsy—Oral CDx—A
noninvasive method for the early detection of precancerous and
cancerous lesions. Journal of Clinical and Diagnostic Research,
2014. 8(2): p. 222-226.
Cannot construct a 2  2 table; 207 patients did not receive confirmation
biopsy
21. Chaudhari, V.V., et al., Sediment cytology in diagnostic evalua-
tion of oral neoplasms. Indian Journal of Dental Research: Official
Publication of indian Society for Dental Research, 2014. 25(2):
p. 147-149.
Details a technique for obtaining cytologic smears from a biopsy specimen
22. Cheng, Y.S., T. Rees, and J. Wright, A review of research on
salivary biomarkers for oral cancer detection. Clinical and Trans-
lational Medicine, 2014. 3(1): p. 3.
Review article about salivary biomarkers
23. Cheng, Y.S., T. Rees, and J. Wright, Updates regarding diagnostic
adjuncts for oral squamous cell carcinoma. Texas Dental Journal,
2015. 132(8): p. 538-49.
Review article
24. Chhabra, N., S. Chhabra, and N. Sapra, Diagnostic modalities for
squamous cell carcinoma: an extensive review of literature-
considering toluidine blue as a useful adjunct. Journal of Maxillo-
facial & Oral Surgery, 2015. 14(2): p. 188-200.
Review of different adjuncts
25. Desai, V.D. and P. Narang, Utility of toluidine blue staining in the
detection of oral epithelial dysplasia: A diagnostic adjunct. Indian
Journal of Public Health Research and Development, 2015. 6(1):
p. 80-85.
Criterion standard applied before index test
26. Dolens Eda, S., et al., Cytopathology: a useful technique for
diagnosing oral lesions? a systematic literature review. Diagnostic
Cytopathology, 2013. 41(6): p. 505-14.
Systematic review
27. Dowthwaite, S., et al., Contact endoscopy as a novel technique in
the detection and diagnosis of oral cavity and oropharyngeal
mucosal lesions in the head and neck. Journal of Laryngology and
Otology, 2014. 128(2): p. 147-152.
No examination of any of the adjuncts of interest
28. Edwards, P.C., Oral cancer screening for asymptomatic adults: Do
the United States Preventive Services Task Force draft guidelines
miss the proverbial forest for the trees?Oral Surgery, Oral Medicine,
Oral Pathology and Oral Radiology, 2013. 116(2): p. 131-134.
Review article of the United States Preventive Services guidelines
29. Elvers, D., et al., Margins of oral leukoplakia: autofluorescence
and histopathology. British Journal of Oral & Maxillofacial Surgery,
2015. 53(2): p. 164-9.
Target condition was not appropriate
30. Epstein, J.B., Screening for oral potentially malignant epithelial
lesions and squamous cell carcinoma: a discussion of benefit and
risk. Journal (Canadian Dental Association), 2014. 80: p. e47.
Review article of the United States Preventive Services guidelines
31. Francisco, A.L., et al., Fluorescence spectroscopy for the detec-
tion of potentially malignant disorders and squamous cell carci-
noma of the oral cavity. Photodiagnosis & Photodynamic Therapy,
2014. 11(2): p. 82-90.
Cannot calculate sensitivity and specificity
32. Frustino, J., et al., Sensitivity and specificity of autofluorescent
screening in addition to white light exam across anatomical subsites
of the oral cavity and oropharynx. Oral Oncology, 2013. 49: p. S49.
Abstract only
33. Fuller, C., et al., Adjunctive diagnostic techniques for oral lesions
of unknown malignant potential: Systematic review with meta-
analysis. Head & Neck, 2015. 37(5): p. 755-62.
Systematic review
34. Gillani, M., et al., Diagnostic accuracy, sensitivity, specificity and
positive predictive value of fine needle aspiration cytology (FNAC) in
intra oral tumors. Asian Pacific Journal of Cancer Prevention: Apjcp,
2012. 13(8): p. 3611-5.
Comparison of fine-needle aspiration versus biopsy in tumors
35. Gillenwater, A.M., et al., Observation of patients with oral
potentially malignant disorders using autofluorescence imaging
and spectroscopy. Otolaryngology—Head and Neck Surgery (United
States), 2013. 1): p. P71-P72.
Abstract only
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36. Giovannacci, I., et al., Non-invasive visual tools for diagnosis of
oral cancer and dysplasia: A systematic review. Medicina Oral,
Patologia Oral y Cirugia Bucal, 2016. 21(3): p. e305-e315.
Systematic review of adjuncts
37. Goodson, M.L., et al., Brush versus scalpel: Consensus agree-
ment on orcellex brush cytology versus incisional biopsy. Oral
Oncology, 2013. 49: p. S96-S97.
Abstract only
38. Gottehrer, N. and J. Martin, Evaluation of salivary transcriptome
markers for early detection of squamous cell cancer in a prospective
blinded trial. Cancer Research. Conference: 106th Annual Meeting
of the American Association for Cancer Research, AACR, 2015. 75(15
SUPPL. 1).
Abstract only
39. Graveland, A.P., et al., Molecular screening of oral precancer.
Oral Oncology, 2013. 49(12): p. 1129-1135.
Cannot calculate sensitivity and specificity
40. Gupta, S., et al., Clinical correlative study on early detection of
oral cancer and precancerous lesions by modified oral brush biopsy
and cytology followed by histopathology. Journal of Cancer
Research and Therapeutics, 2014. 10(2): p. 232-238.
Cannot construct a 2  2 table; criterion standard not applied to all lesions
41. Gupta, V. and K.M. Hiwale, Oral lesions: A comparative study of
cytology and histopathology in rural population of India. Acta
Cytologica, 2013. 57: p. 105.
Abstract only
42. Gupta, V., K.M. Hiwale, and A. Bhake, Cytopathological criteria
of oral carcinoma: A study in rural population of India. Acta Cyto-
logica, 2013. 57: p. 107.
Abstract only
43. Hartmann, S., et al., Oral brush biopsy and melanoma-
associated antigens A (MAGE-A) staining in clinically suspicious
lesions. Journal of Cranio-Maxillofacial Surgery, 2015. 43(10):
p. 2214-2218.
Biomarkers were measured from the biopsy specimen; not a salivary
diagnostic
44. Jayanth Kumar, V. and T.N. Uma Maheswari, In-vivo auto-
fluorescence spectroscopy in oral cancer diagnosis: A systematic
review. International Journal of Pharma and Bio Sciences, 2014.
5(1): p. B252-B260.
Systematic review
45. Jayaprakash, V., et al., Autofluorescence visualization for
detecting potentially malignant white oral mucosal lesions. Oral
Oncology, 2013. 49: p. S50.
Abstract only
46. Jo, J.A., et al., In vivo early detection of oral epithelial cancer by
endogenous fluorescence lifetime imaging (FLIM) Endoscopy. Mo-
lecular Imaging and Biology, 2016. 1): p. S1359-S1360.
Poster presentation
47. Kabiraj, A., et al., Screening of oral potentially malignant dis-
orders using exfoliative cytology: A diagnostic modality. Journal of
Cancer Epidemiology, 2016. 2016 (no pagination)(8134832).
No criterion standard
48. Kasthuri, M., et al., Toluidine blue staining in the diagnosis of
oral precancer and cancer: Stains, technique and its uses—A review.
Biomedical and Pharmacology Journal, 2015. 8SE: p. 519-522.
Review article
49. Kaur, J. and R. Jacobs, Combination of autofluorescence imaging
and salivary protoporphyrin in oral precancerous and cancerous
lesions: Non-invasive tools. Journal of Clinical & Experimental
Dentistry, 2015. 7(2): p. e187-191.
Case-control study
50. Kaur, M., et al., Evaluation of brush cytology and DNA image
cytometry for the detection of cancer of the oral cavity. Diagnostic
Cytopathology, 2016. 44(3): p. 201-205.
Cytologic testing with DNA image cytometry
51. Kordbacheh, F., N. Bhatia, andC.S. Farah, Patterns of differentially
expressed genes in oral mucosal lesions visualised under auto-
fluorescence (VELscopeTM). Oral Diseases, 2016. 22(4): p. 285-296.
Adjunct was not applied clinically.
52. Krishnan, R., et al., Association of serum and salivary tumor
necrosis factor-alpha with histological grading in oral cancer and its
role in differentiating premalignant and malignant oral disease.
Asian Pacific Journal of Cancer Prevention: Apjcp, 2014. 15(17):
p. 7141-7148.
Case-control study; cannot tell which patients were included in sensitivity
and specificity calculations
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53. Kulapaditharom, B. and V. Boonkitticharoen, Laser-induced
fluorescence imaging in localization of head and neck cancers. Ann
Otol Rhinol Laryngol, 1998. 107(3): p. 241-246.*
Cannot construct 2  2 table
54. Lalla, Y., M. Matias, and C.S. Farah, Oral mucosal disease in an
Australian urban Indigenous community using autofluorescence
imaging and reflectance spectroscopy. Australian Dental Journal,
2015. 60(2): p. 216-224.
Cannot construct a 2  2 table; only 2 participants received the criterion
standard
55. Laronde, D.M., et al., Decision making on detection and triage of
oral mucosa lesions in community dental practices: screening de-
cisions and referral. Community Dentistry & Oral Epidemiology,
2014. 42(4): p. 375-384.
Use of VELscope was exploratory; no criterion standard applied
56. Leon, M., B. Centeno, and E. Kostas-Polston, Comparison of
liquid based cytology of direct brush and saliva specimens in oral
and oropharyngeal squamous cell carcinomas. Laboratory Investi-
gation, 2015. 95: p. 96A.
Data for histologic diagnosis not available
57. Liao, L.J., et al., Initial outcomes of an integrated outpatient-
based screening program for oral cancers. Oral Surgery, Oral
Medicine, Oral Pathology and Oral Radiology, 2015. 119(1):
p. 101-106.
No mention of the adjuncts of interest
58. Liu, D., et al., Non-invasive techniques for detection and diag-
nosis of oral potentially malignant disorders. Tohoku Journal of
Experimental Medicine, 2016. 238(2): p. 165-177.
Review of adjuncts
59. Ma, J.M., et al., Brush biopsy with DNA-image cytometry: a
useful and noninvasive method for monitoring malignant trans-
formation of potentially malignant oral disorders. European
Archives of Oto-Rhino-Laryngology, 2014. 271(12): p. 3291-3295.
Cytologic testing with DNA image cytometry
60. Mandlik, D., et al., Use of 90 Hopkin’s telescopic examination as
an OPD tool to clinically evaluate and record oral cavity lesions: Our
experience in early detection, especially in patients with limited
mouth opening. Journal of Clinical and Diagnostic Research, 2015.
9(6): p. XC01-XC04.
90 Hopkin telescopic examination not an adjunct of interest; patients with
confirmed oral squamous cell carcinoma in the study sample
61. Marques, A.E., et al., Assessing oral brushing technique as a
source to collect DNA and its use in detecting human papilloma-
virus. Pathology, Research & Practice, 2013. 209(5): p. 291-295.
Human papilloma virus diagnosis in healthy people with brush cytologic
testing; no criterion standard was applied
62. McNamara, K.K., et al., The role of direct visual fluorescent ex-
amination (VELscope) in routine screening for potentially malignant
oral mucosal lesions. Oral Surgery, Oral Medicine, Oral Pathology
and Oral Radiology, 2012. 114(5): p. 636-643.
Criterion standard not applied to the whole population
63. Messadi, D.V., Diagnostic aids for detection of oral precancerous
conditions. International Journal of Oral Science, 2013. 5(2):
p. 59-65.
Review article
64. Messadi, D.V., et al., The clinical effectiveness of reflectance
optical spectroscopy for the in vivo diagnosis of oral lesions.
International Journal of Oral Science, 2014. 6(3): p. 162-167.
Cannot construct a 2  2 table because the authors report only cluster of
differentiation 4 counts not a final diagnosis
65. Mori, K., et al., Oral cancer diagnosis via a ferrocenylnaph-
thalene diimide-based electrochemical telomerase assay. Clinical
Chemistry, 2013. 59(1): p. 289-295.
Oral squamous cell carcinomas were confirmed already; adjunct not of
interest
66. Nagi, R., et al., Efficacy of light based detection systems for early
detection of oral cancer and oral potentially malignant disorders:
Systematic review. Medicina Oral, Patologia Oral y Cirugia Bucal,
2016. 21(4): p. e447-e455.
Systematic review
67. Navone, R., et al., Diagnostic cytopathology and DNA HPV testing
for oral cancer screening. Oral Diseases, 2016. 22: p. 35.
Abstract only
68. Navone, R., et al., Oral microhistology: An innovative technique
for oral lesion diagnosis. Oral Diseases, 2016. 22: p. 36.
Conference abstract
69. Ohnishi, Y., et al., Usefulness of a fluorescence visualization
system for the detection of oral precancerous and early cancerous
lesions. Oncology Reports, 2016. 36(1): p. 514-520.
Rat model; patients already had oral cancer
70. Omar, E.A., Current concepts of optical biopsy in diagnosis of
oral squamous cell carcinoma (OSCC): Literatures review. Head and
Neck, 2015. 37: p. E133-E134.
Conference abstract
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71. Paderni, C., et al., Direct visualization of oral-cavity tissue
fluorescence as novel aid for early oral cancer diagnosis and
potentially malignant disorders monitoring. International Journal
of Immunopathology & Pharmacology, 2011. 24(2 Suppl): p. 121-128.
Cannot construct a 2  2 table; thresholds are not clear for positivity
72. Porter, S., et al., Non-invasive diagnostic AIDS for oral cancer
and epithelial dysplasia. Oral Diseases, 2016. 22: p. 23.
Abstract only
73. Rashid, A. and S. Warnakulasuriya, The use of light-based (op-
tical) detection systems as adjuncts in the detection of oral cancer
and oral potentially malignant disorders: A systematic review.
Journal of Oral Pathology and Medicine, 2015. 44(5): p. 307-328.
Systematic review
74. Remmerbach, T.W., et al., Toward a multimodal cell analysis of
brush biopsies for the early detection of oral cancer. Cancer, 2009.
117(3): p. 228-235.*
Cannot construct a 2  2 table
75. Richards, D., Adjunctive tests cannot replace scalpel biopsy for
oral cancer diagnosis. Evidence-Based Dentistry, 2015. 16(2): p. 46-47.
Commentary
76. Sahebjamee, M., et al., Conventional versus Papanicolaou-stained
cytobrush biopsy in the diagnosis of oral squamous cell carcinoma.
Oral Health & Dental Management, 2014. 13(3): p. 619-622.
Cannot construct a 2  2 table
77. Salih, M.M., O.H. Maha, and A.H.E. Nabi, Comparison between
exfoliative cytology and histopathology in detecting oral squamous
cell carcinoma. Acta Cytologica, 2016. 60: p. 215.
Abstract only
78. Santos, A., et al., Oral cancer’s early diagnosis: The contribution
of contact endoscopy. Otolaryngology–Head and Neck Surgery
(United States), 2014. 1): p. P61.
Abstract only
79. Santos, T., et al., Toluidine blue can be useful to identify severe
oral dysplasia with high Ki-67 Labeling index. Oral Oncology, 2013.
49: p. S131.
Abstract only
80. Sawan, D. and A. Mashlah, Evaluation of premalignant and
malignant lesions by fluorescent light (VELscope). Journal of Inter-
national Society of Preventive & Community Dentistry, 2015. 5(3):
p. 248-254.
Cannot construct a 2  2 table
81. Sekine, J. and H. Sasaki, Diagnostic performance of oral cancer
cytology in a pilot study. Acta Cytologica, 2016. 60: p. 137.
Conference abstract
82. Siebers, T.J.H., et al., The value of the oral brush in identifying
precancerous and cancerous lesions. Oral Oncology, 2013. 49: p. S70.
Abstract only
83. Sharwani, A., et al., Fluorescence spectroscopy combined with
5-aminolevulinic acid-induced protoporphyrin IX fluorescence in
detecting oral premalignancy. J Photochem Photobiol B, 2006. 83(1):
p. 27-33.*
5-Aminolevulinic acid not commercially available in the United States
84. Sharwani, A., et al., Assessment of oral premalignancy using
elastic scattering spectroscopy. Oral Oncol, 2006. 42(4): p. 343-349.*
Elastic scattering spectroscopy not commercially available in the United
States
85. Spivakovsky, S. and M.G. Gerber, Little evidence for the effec-
tiveness of chemiluminescence and autofluorescent imaging de-
vices as oral cancer screening adjuncts. Evidence-Based Dentistry,
2015. 16(2): p. 48.
Commentary
86. Sudheendra, U.S., H.S. Sreeshyla, and R. Shashidara, Vital tissue
staining in the diagnosis of oral precancer and cancer: Stains,
technique, utility, and reliability. Clinical Cancer Investigation
Journal, 2014. 3(2): p. 141-145.
Review article
87. Vashisht, N., et al., Chemiluminescence and Toluidine blue as
diagnostic tools for detecting early stages of oral cancer: An invivo
study. Journal of Clinical and Diagnostic Research, 2014. 8(4).
Cannot construct a 2  2 table
88. Wang, J.H., et al., Bimodal optical diagnostics of oral cancer
based on Rose Bengal conjugated gold nanorod platform. Bio-
materials, 2013. 34(17): p. 4274-4283.
Phase 1 study
89. Yang,S.W., etal., Lightsourcesused inevaluatingoral leukoplakia:
Broadband white light versus narrowband imaging. International
Journal of Oral andMaxillofacial Surgery, 2013. 42(6): p. 693-701.
Adjunct is endoscopy.
90. Leunig, A., et al., Detection of squamous cell carcinoma of the
oral cavity by imaging 5-aminolevulinic acid-induced protoporphy-
rin IX fluorescence. Laryngoscope, 2000. 110(1): p. 78-83.*
5-Aminolevulinic acid not commercially available in the United States
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Mashberg,55 1980 United
States
Veterans
Administration
medical center,
secondary
The investigators
conducted a
thorough
examination of the
oral soft tissue in
most patients; if
asymptomatic
mucosal alterations
were visible, then the
investigators referred
patients for an
evaluation, and then
rescheduled the
patients 10 to 14
days later for
reevaluation and
tuberculosis testing.
Implied that the 14-
day period was part
of the recruitment
process and that
patients were not
deemed part of the
study if the lesions
did not persist.
Conditions recorded:
squamous cell
carcinoma (invasive),
carcinoma in situ,
atypia, and benign
(hyperplasia,
keratosis,
inflammation, and so
on)
Not reported Not reported Vital staining,
toluidine blue
235 Asymptomatic
mucosal alterations
Silverman and
Colleagues,58
1984
United
States
Oral medicine clinic,
secondary
“The study group
comprised 132
consecutive patients
seen in the oral
medicine clinic who
were suspected of
having oral
carcinomas or
precancerous
(dysplastic) lesions.”
Not reported Not reported Vital staining,
toluidine blue
132 “Suspected of having
oral carcinomas or
precancerous
(dysplastic) lesions”
Warnakulasuriya
and Johnson,60
1996
Sri Lanka
and
Pakistan
Dental surgeon
clinic, secondary
All patients had been
referred to, or had
attended, the
specialist centers
with unconfirmed
oral mucosal lesions.
60 (15) Female: 29
(28.4), male:
73 (71.6)
Vital staining,
OraScan (Zila Inc.),
toluidine blue
86 Invasive and
dysplastic lesions
(such as benign
keratoses)
Onizawa and
Colleagues,29
1999
Japan Oral and
maxillofacial division
at hospital, tertiary
Participants had been
referred to the
Division of Oral and
Maxillofacial Surgery,
University Hospital of
Tsukuba Hospital,
Japan, for
examination and
treatment of oral
lesions.
23-92, 60 Female: 53
(40.8), male:
77 (59.2)
Autofluorescence,
fluorescence
photography with
ultraviolet flash
124 Unclear
* We compared all index tests against biopsy results as the criterion standard.
† The target condition was oral squamous cell carcinoma, potentially malignant disorders, or dysplasia in all studies.
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Sciubba,44 1999 United
States
Dentists specializing
in oral and
maxillofacial
pathology, oral
medicine, and oral
surgery obtained the
specimens in the
course of their
routine clinical
practice, secondary
“Suspicious lesions
(categorized as Class
I) were analysed
by use of both
OralCDx (OralScan
Laboratories, Inc.)
and scalpel biopsy.
Apparently innocuous
lesions (categorized
as Class II) that, in the
investigators’ opinion,
required no further
attention other than
clinical follow-up
were tested only by
use of OralCDx.
Patients with
apparently innocuous
lesions that produced
abnormal OralCDx
results, as defined
below, subsequently
were subjected to
scalpel biopsy at the
investigators’
discretion.”
18-83, 55 Female: 502
(53), male:
443 (47)
Cytologic testing,
OralCDx
298 “Intraoral lesions
displaying an
epithelial
component” then
classified into
suspicious and
innocuous
Onofre and
Colleagues,57
2001
Brazil Hospital-based
sample, tertiary
“Fifty patients with
potentially malignant
epithelial lesions and
superficial oral
ulcerations
suggestive of
malignancy were
selected from those
treated at the Oral
Medicine Service,
Faculty of Dentistry,
Araraquara, Brazil
from August 1993 to
May 1995 (n ¼
1957).” “Not included
in this study were
patients who refused
to be submitted to
biopsy (n ¼ 21),
those who
abandoned
treatment, or those
who had clinically
obvious invasive
carcinomas or lesions
without risk or
suspicion of
malignancy.”
55.2 (13.4) Female: 22
(44), male: 28
(56)
Vital staining,
toluidine blue
50 Potentially malignant
epithelial lesions and
superficial oral
ulcerations
suggestive of
malignancy
Svirsky and
Colleagues,46
2002
United
States
Pathology
laboratories,
secondary
Method of patient
selection: 298
patients underwent
scalpel biopsy who
also had undergone
brush biopsy that had
abnormal results
18-89, 52 Female: 146
(51), male:
152 (49)
Cytologic testing,
OralCDx
298 Patients undergoing
brush biopsy
Cheng and
Yang,53 2003a
China University clinic,
secondary
Patients with
mucosal lesion
7-76, 58.3 Female: 53
(89), male: 7
(11)
Vital staining, Oratest
(Zila Inc.) rinse
30 Not stated
Cheng and
Yang,53 2003b
China University clinic,
secondary
Patients with
mucosal lesion
7-76, 58.3 Female: 53
(89), male: 7
(11)
Vital staining, Oratest
stain
30 Not stated
Navone and
Colleagues,39
2004
Italy Oral pathology
service of university
hospital, tertiary
Method of patient
selection: patients
with lesions clinically
identified as
suggestive of
carcinoma or
dysplasia
68.9 (14.33) Female: 44
(49), male: 45
(51)
Cytologic testing,
Cytobrush (Cooper
Surgical)
78 Unclear
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Scheifele and
Colleagues,43
2004
Germany Hospital-based
sample, tertiary
80 consecutive
patients between July
2002 and September
2003. Inclusion
criteria: “(1) an
OralCDx brush biopsy
of a lesion with the
clinical diagnosis oral
leukoplakia (OL), oral
lichen planus (OLP),
or obvious oral
squamous cell
carcinoma (OSCC);
and (2) a scalpel
biopsy that had been
performed within
one month before or
after the brush biopsy
of the same lesion.”
Only those who
underwent scalpel
biopsy were included
in the study, not full
spectrum of disease,
leading to potential
sampling bias
58.6 (13.1) Female: 33
(41.3), male:
47 (58.8)
Cytologic testing,
OralCDx
96 OralCDx brush
biopsy of a lesion
with the clinical
diagnosis of oral
leukoplakia, oral
lichen planus, or oral
squamous cell
carcinoma
Chen and
Colleagues,52
2007
Taiwan Unclear Suspicious oral
lesions
Not reported Not reported Vital staining,
methylene blue
58 Homogeneous
leukoplakia,
heterogeneous
leukoplakia,
erythroplakia, and
ulceration
Du and
Colleagues,54
2007
China Hospital, tertiary Superficial ulceration
suggestive of
malignancy: oral
leukoplakia, oral
lichen planus, oral
leukokeratosis
Excluded: benign oral
lesions and lesions
without a histologic
result after clinical
diagnosis
50.1 (12.6) Female: 67
(52.3), male:
61 (47.7)
Vital staining, rose
bengal
128 All patients
suspected of having
malignancy,
leukoplakia, lichen
planus, or
leukokeratosis
Farah and
McCullough,63
2007
Australia Oral medicine
specialist, tertiary
55 patients referred
to an oral medicine
specialist service over
a 3-month period for
assessment of an oral
mucosal white lesion
were screened
prospectively with
ViziLite (DenMat
Holdings, LLC)
Female: 58.7
(2.47), male:
56.81 (2.2)
Female: 29
(53), male: 26
(47%)
Tissue reflectance,
ViziLite
55 Oral mucosal white
lesion
Gupta and
Colleagues,70
2007
India Otorhinolaryngology
outpatient clinic,
secondary
Screening of 96
patients with
suspicious oral
lesions who sought
care at the
outpatients
clinics of the
Otorhinolaryngology
Department,
Swaroop Rani Nehru
Hospital, Allahabad,
India
Benign and
malignant:
19-75, 38;
squamous
cell
carcinoma:
35-74, 52
Benign and
malignant:
female: 22
(34.4), male:
42 (65.6);
squamous cell
carcinoma:
female: 8 (25),
male: 24 (75)
Cytologic testing and
vital staining,
toluidine blue and
brush cytologic
testing
96 “Suspicious pre-
malignant or
malignant lesions of
the oral cavity
irrespective of site,
stage and sex were
selected.”
Epstein and
Colleagues,67
2008
United
States
University and cancer
clinics, secondary
Investigators
identified patients
who had a history of
oral lesions or were
at high risk of
developing an oral
lesion and asked
them to participate.
59.64
(12.53)
Female: 43
(51.19); male:
41 (48.8)
Tissue reflectance
and vital staining,
ViziLite and toluidine
blue
97 Patients identified
with a lesion at
conventional visual
examination
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Mehrotra and
Colleagues,37
2008
India Otorhinolaryngology
and pathology
department at
medical college,
secondary
“Ninety-four patients
with suspicious oral
lesions from
Departments of
Otorhinolaryngology
and Pathology, Moti
Lal Nehru Medical
College, Allahabad,
India, were studied in
a random manner.”
10-80 Female: 19
(24), male: 60
(76)
Cytologic testing,
baby toothbrush
79 “Only lesions with an
abnormal epithelial
surface including
erythroplakia,
leukoplakia without
dysplasia and oral
submucous fibrosis
were included.”
Navone and
Colleagues,40
2008
Italy Oral medicine
section of a
university hospital,
tertiary
Patients with oral
potentially malignant
epithelial lesions,
referred to the Oral
Medicine Section of
the University of
Turin, Turin, Italy,
entered this study.
Patients with clinical
features suggestive of
carcinoma were not
excluded. “In the
present study, all
included patients
already had a
clinically suspicious
lesion.”
Not reported Not reported Cytologic testing,
curette
158 Potentially malignant
epithelial lesions
Allegra and
Colleagues,48
2009
Italy Department of
otolaryngology–head
and neck surgery,
tertiary
Patients with oral
mucosal lesions
42-82, 59 Female: 13
(40.6), male:
19 (59.4)
Vital staining,
toluidine blue
45 Nonneoplastic, mild
dysplasia, moderate
dysplasia, severe
dysplasia, in situ
carcinoma, invasive
carcinoma
McIntosh and
Colleagues,64
2009
Australia Oral medicine
specialist unit,
tertiary
“Patients presenting
to an oral medicine
specialist unit for
assessment of an oral
mucosal lesion were
recruited into the
study.” “The only
criterion for inclusion
was referral for
examination of an
oral mucosal white
lesion that was
deemed to be
clinically suspicious
and warranted
further evaluation by
routine measures
including definitive
histopathology.”
26-87.2, 56.6 Female: 27
(54), male: 23
(46)
Tissue reflectance,
Microlux (AdDent
Inc.)
50 “Clinically suspicious
lesions, sufficient to
be referred to an oral
medicine specialist
unit for assessment”
Delavarian and
Colleagues,32
2010
Iran University clinic,
secondary
Lesions clinically
diagnosed as oral
potentially malignant
lesions (leukoplakia)
or malignant lesions
(oral squamous cell
cancer and verrucous
carcinoma)
22-79, 54
(17.38)
Female: 12
(48), male: 13
(52)
Cytologic testing,
OralCDx
26 Lesions clinically
diagnosed as oral
potentially malignant
lesions (leukoplakia)
or malignant lesions
(oral squamous cell
cancer and verrucous
carcinoma)
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Mehrotra and
Colleagues,28
2010
India Outpatient
department of
hospital, secondary
Patients selected for
study after detection
of a clinically
innocuous lesion
(Class II) during
routine dental care
“Patients with Class II
lesions for
subsequent
evaluation with the
light-based adjunct
screening tools ..
We excluded patients
with Class I lesions
detected with a
conventional
overhead
examination light
(and referred them
for treatment) and
those without any
oral lesions.”
Median: 41 Male to female
ratio of 7.5:1
Autofluorescence,
VELscope (LED
Dental)
156 Identified as Class II
before biopsy, so
patients with lesions
classified as Class I
(“suspicious enough
to warrant a biopsy”)
were excluded
Mehrotra and
Colleagues,28
2010
India Outpatient
department of
hospital, secondary
Method of patient
selection: patients
selected for study
after detection of a
clinically innocuous
lesion (Class II)
during routine dental
care “Patients with
Class II lesions for
subsequent
evaluation with the
light-based adjunct
screening tools ..
We excluded patients
with Class I lesions
detected with a
conventional
overhead
examination light
(and referred them
for treatment) and
those without any
oral lesions.”
Median: 39 Male to female
ratio of 8.7:1
Tissue reflectance
and vital staining,
ViziLite Plus (DenMat
Holdings, LLC)
102 Identified as Class II
before biopsy, so
patients with lesions
classified as Class I
(“suspicious enough
to warrant a biopsy”)
were excluded
Nagaraju and
Colleagues,56
2010
India Department of oral
medicine and
radiology, dental
college and hospital,
secondary
The study group
consisted of 60
participants of both
sexes, 30 participants
with clinically
suspicious
premalignant lesions
and 30 participants
with clinically
suspicious malignant
lesions. “Subjects
who fulfilled the
following criteria
were selected for the
study: leukoplakia,
speckled leukoplakia,
erosive lichen planus,
oral malignancy.”
Not reported Not reported Vital staining,
toluidine blue and
Lugol iodine
60 Premalignant lesions
(degree of
dysplasia), malignant
lesions (degree of
differentiation)
Awan and
Colleagues,24
2011a
United
Kingdom
Oral medicine clinics,
secondary
Patients seeking care
at an oral medicine
clinic with white, red,
or mixed lesions
58.5 (11.9) Female: 56
(44.4), male:
70 (55.6)
Autofluorescence,
VELscope
116 White, red, and
mixed white and red
patches
Awan and
Colleagues,66
2011b
United
Kingdom
Oral medicine clinics,
secondary
Patients seeking care
at an oral medicine
clinic with white, red,
or mixed lesions
58.5 (11.9) Female: 56
(44.4), male:
70 (55.6)
Tissue reflectance,
ViziLite
116 White, red, and
mixed white and red
patches
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Cancela-
Rodriguez and
Colleagues,50
2011
Spain University clinic,
secondary
Patients with
mucosal lesions
13-100, 55.3
(16.1)
Female: 83
(51.9), male:
77 (48.1)
Vital staining,
toluidine blue
160 Participants with
benign lesions or
clinically suspicious
premalignant or
malignant lesions
that were white or
red, exophytic, or
manifesting as
nonhealing ulcers
Guneri and
Colleagues,69
2011
Turkey University clinic,
secondary
“Thirty-five patients
with oral mucosal
lesions identified by
the Orofacial Lesions
Council of Ege
University, Izmir,
Turkey, were seen for
further evaluation.”
56.2 Female: 22
(62.9), male:
13 (37.1)
Cytologic testing and
vital staining,
toluidine blue and
Cytobrush
43 “Lesions selected for
further examination
with Tblue staining
and brush cytology
were homogenous
and non-
homogenous
leukoplakia, reticular
erosive/ulcerated
lichenoid lesions,
and superficial
ulcerations
suspicious of
malignancy.”
Koch and
Colleagues,35
2011a
Germany Maxillofacial surgery
clinic in a hospital,
tertiary
“All patients attended
the Maxillofacial
Surgery Clinic at the
University Hospital in
Mainz, Germany and
were examined
between September
2005 and December
2007.to be
included lesion was
required to be
clinically diagnosed
as SCC or suspicious
epithelial lesion and
most suspicious area
of lesion was tested
and biopsied”
62.8 (18.3) Approximately
2:1 (unclear)
Cytologic testing,
Cytobrush Plus GT
(Cooper Surgical)
182 Clinically diagnosed
as squamous cell
carcinoma or
suspicious epithelial
lesions
Koch and
Colleagues,27
2011b
Germany Maxillofacial surgery
clinic, secondary
“78 patients
participating in the
study attended the
outpatient clinic of
the Oral and
Maxillofacial Surgery
clinic of the Mainz
University Medical
Centre and suffered
from suspicious oral
mucosal lesions”
61.7 Female: 32
(41), male: 46
(59%)
Autofluorescence,
“Two different
investigation
methods were
applied: the standard
examination by white
light and the
examination by a
400-nanometer
wavelength light
source that is
supposed to trigger a
green light emission
(>500 mm) in
normal mucosa.”
Documented with
digital reflex
photography
78 41% red, like
erythroplakia (17%)
or erythroleukoplakia
(24%); 21% white,
like leukoplakia
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Mehrotra and
Colleagues,36
2011
India Outpatient
otorhinolaryngology
department at a
medical college,
secondary
“Patients who were
at least 18 years of
age presenting with
unrelated complaints
to the outpatient
Department of
Otorhinolaryngology,
Moti Lal Nehru
Medical College in
Allahabad, were
screened by a team
of specialist and
residents-in-training
between July and
November 2010.
Patients with an oral
epithelial
abnormality that
appeared clinically
benign—minimally
suspicious—and did
not have an obvious
etiology such as
trauma or infection
were prospectively
enrolled.” “Patients
with oral lesions
suggestive of
dysplasia or cancer
were excluded.”
25-75, 45.5 Female: 30
(35.3), male:
55 (64.7)
Cytologic testing,
OralCDx
79 “Patients with an oral
epithelial
abnormality that
appeared clinically
benign—minimally
suspicious—and did
not have an obvious
etiology such as
trauma or infection
were prospectively
enrolled.”
Scheer and
Colleagues,31
2011
Germany Department of oral
and
craniomaxillofacial
surgery, secondary
“Oral and VELscope
examinations were
performed on 64
patients referred
to the Department
of Oral and
Craniomaxillofacial
Surgery to rule out
invasive squamous
cell carcinoma.”
“Patients with
advanced squamous
cell carcinomas were
excluded.” Twenty
patients with
previous history
raised concern that
examiners were
already aware of
patients’ diagnoses
59.8 Female: 25
(39.1), male:
39 (60.9)
Autofluorescence,
VELscope
64 Patients with
advanced squamous
cell carcinoma
excluded
Upadhyay and
Colleagues,59
2011
India College of dental
science clinic,
secondary
“47 patients visiting
the Dental clinics of
Manipal College of
Dental Sciences,
Manipal”
31-75, 53.83 Female: 10
(21.3), male:
37 (78.7)
Vital staining,
toluidine blue
47 “Clinically a
provisional diagnosis
of homogeneous
Leukoplakia,
speckled
Leukoplakia,
Erythroplakia &
Erosive lichen
planus”
Awan and
Colleagues,49
2012
United
Kingdom
Oral medicine clinics
at 2 London, UK,
hospitals, secondary
Patients seeking care
at an oral medicine
clinic with white, red,
or mixed lesions
Older than
16
Female: 36
(39), male: 56
(61)
Vital staining,
toluidine blue
92 White, red, and
mixed white and red
patches
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Farah and
Colleagues,25
2012
Australia Oral medicine
specialist unit,
tertiary
“Patients presenting
to an oral medicine
specialist unit for
assessment of an oral
mucosal lesion were
recruited into the
study.” “Patients
known to have oral
epithelial dysplasia or
squamous cell
carcinoma were not
included in this
study.”
Female: 59.1
(12.8), Male:
57.8 (11.88)
Female: 66
(58.9), male:
46 (41.1)
Autofluorescence,
VELscope
118 Severity: “oral
mucosal white or
mixed red/white
lesion that was
deemed . to be
clinically suspicious”
Mojsa and
Colleagues,68
2012
Poland University medical
college, secondary
Method of patient
selection: “Thirty
consecutive patients
with lesions
suggestive of being
premalignant
identified by a
conventional clinical
oral examination
under incandescent
light were included
into the study.”
23-80, 50.3
(15.7)
Female: 9
(30), male: 21
(70)
Tissue reflectance
and vital staining,
ViziLite Plus
41 Not stated
Ng and
Colleagues,41
2012
Canada Community referral-
based oral medicine
clinic, secondary
“Retrospective
chart review of a
consecutive selection
of patients who
had both a biopsy
and a concurrent
QC assessment
from 2008 to 2010”
“Patients . with
suspicious oral
lesions were
evaluated with
concurrent but
independent HP and
quantitative cytology
assessments.”
Median: 58 Female: 89
(52.0), male:
82 (48)
Cytologic testing, Oral
Advance
171 Potentially malignant
disorders and oral
squamous cell
carcinoma
Rahman and
Colleagues,42
2012
India 3-day screening
camp, primary
Investigators issued
pamphlets inviting
people to a self-
examination 3-day
event; 849 attended,
158 had red and
white lesions, only
86 consented. “The
study included 86
participants
suspected of having
oral premalignant
lesions or OSCC.”
26-60, 43
(12.53)
Female: 18
(21.0), male:
68 (79.1)
Vital staining,
Cytobrush
86 “Suspected of having
oral premalignant
lesions or oral
squamous cell
carcinoma”
Rahman and
Colleagues,42
2012
India 3-day screening
camp, primary
Investigators issued
pamphlets inviting
people to a self-
examination 3-day
event; 849 attended,
158 had red and
white lesions, only
86 consented. “The
study included 86
participants
suspected of having
oral premalignant
lesions or OSCC.”
26-60, 43
(12.53)
Female: 18
(21.0), male:
68 (79.1)
Cytologic testing,
Cytobrush
86 “Suspected of having
oral premalignant
lesions or oral
squamous cell
carcinoma”
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Seijas-Naya and
Colleagues,45
2012
Spain University oral
medicine, oral
surgery and
implantology
department,
secondary
“Samples obtained
through OralCDx 
on 24 patients who
visited the Master of
Oral Medicine, Oral
Surgery and
Implantology of the
University of Santiago
de Compostela,
referred by the
SERGAS (Servizo
Galego de Saúde—
Galician Public
Healthcare System),
between February
2009 and May 2010
who showed clinical
and histological
lesions that were
consistent with oral
leukoplakia in
different clinical
forms”
62.38
(12.14)
Female: 12
(50), male: 12
(50)
Cytologic testing,
OralCDx
24 “Showed clinical and
histological lesions
that were consistent
with oral leukoplakia
in different clinical
forms”
Ujaoney and
Colleagues,65
2012
India Oral diagnosis,
medicine, and
radiology
department at a
dental college,
secondary
“Consecutive
outpatients who
visited the study
centre and who
clinically presented
with at least one
precancerous lesion
were recruited in this
study.”
44.4 (17.1) Female: 4
(7.3), male: 51
(92.7)
Tissue reflectance
and vital staining,
ViziLite Plus
99 Lesions other than
Class I (clinically
diagnosed)
Ujaoney and
Colleagues,65
2012
India Oral diagnosis,
medicine, and
radiology
department at a
dental college,
secondary
“Consecutive
outpatients who
visited the study
centre and who
clinically presented
with at least one
precancerous lesion
were recruited in this
study.”
44.4 (17.1) Female: 4
(7.3), male: 51
(92.7)
Tissue reflectance,
ViziLite
99 Lesions other than
Class I (clinically
diagnosed)
Chaudhari and
Colleagues,51
2013
India Yerwada Central Jail,
primary and
secondary
Investigators
suspected 175
inmates of having
lesions at risk of
developing into
a malignancy
(precancerous
lesions and
conditions) and
malignant lesions.
19-69, 34.98
(12.65)
Female: 0 (0),
male: 82 (100)
Vital staining,
toluidine blue
82 Inmates suspected
of having lesions at
risk of developing
into a malignancy
(precancerous
lesions and
conditions) and
malignant lesions
Chaudhari and
Colleagues,51
2013
India Yerwada Central Jail,
primary and
secondary
Investigators
suspected 175
inmates of having
lesions at risk of
developing into
a malignancy
(precancerous
lesions and
conditions) and
malignant lesions.
19-69, 34.98
(12.65)
Female: 0 (0),
male: 82 (100)
Vital staining, Lugol
iodine
82 Inmates suspected
of having lesions at
risk of developing
into a malignancy
(precancerous
lesions and
conditions) and
malignant lesions
Fontes and
Colleagues,33
2013
Brazil Outpatient clinic at a
hospital, secondary
The study sample
consisted of 172
patients with oral
lesions clinically
suggestive of
malignancy.
20-93 Female: 58
(33.7), male:
114 (66.3)
Cytologic testing,
Cytobrush
164 Oral lesions
suggestive of
malignancy
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Hanken and
Colleagues,26
2013
Germany Department of oral
and maxillofacial
surgery, secondary
120 patients with
suspicious oral
premalignant lesions
(leukoplakia,
erythroplakia, lichen
planus, or pemphigus
vulgaris)
41-76 Female: 35
(58.3), male:
25 (41.7)
Autofluorescence,
VELscope
60 Suspicious oral
premalignant lesions
Kammerer and
Colleagues,34
2013
Germany Department of oral
and maxillofacial
surgery, secondary
Investigators included
88 oral lesions of
uncertain class in this
study. Investigators
included only
clinically suspicious
but not evidently
malignant oral
lesions.
27-88, 62 Female: 25
(35.7), male:
45 (64.3)
Cytologic testing,
Cytobrush Plus GT
76 Uncertain class
Petruzzi and
Colleagues,30
2014
Italy Oral pathology and
medicine outpatient
clinic, secondary
Patients with a
history of oral lesions
or at high risk of
developing oral
lesions
56.7 Female: 22
(45.0), male:
27 (55.0)
Autofluorescence,
VELscope
56 Clinically suspicious
lesions (premalignant
or malignant oral
mucosal lesions)
Chainani-Wu and
Colleagues,62
2015
United
States
Oral medicine clinic,
secondary
Patients seeking care
at the tertiary oral
medicine referral
clinic at the University
of California, San
Francisco for initial
or follow-up
evaluations, who
had oral leukoplakia,
erythroleukoplakia,
or erythroplakia
diagnosed
42-90, 61
(10.6)
Female: 20
(46.5), male:
23 (53.5)
Tissue reflectance,
ViziLite
70 Higher-risk oral
premalignant lesions
or higher-risk areas
within lesions were
important.
Chainani-Wu and
Colleagues,62
2015
United
States
Oral medicine clinic,
secondary
Patients seeking care
at the tertiary oral
medicine referral
clinic at the University
of California, San
Francisco for initial
or follow-up
evaluations, who
had oral leukoplakia,
erythroleukoplakia,
or erythroplakia
diagnosed
42-90, 61
(10.6)
Female: 20
(46.5), male:
23 (53.5)
Tissue reflectance
and vital staining,
ViziLite and toluidine
blue
70 Higher-risk oral
premalignant lesions
or higher-risk areas
within lesions were
important.
Singh and
Shukla,61 2015
India Department of
otorhinolaryngology
and head and neck
surgery, secondary
50 patients with
lesions in the oral
cavity that were
suggestive of
malignancy. The most
common symptoms
for seeking care was
a nonhealing ulcer in
the oral cavity (88%)
followed by pain
(44%), face swelling
(22%), neck swelling
(12%), growth
(10%), difficulty in
swallowing (6%),
reduced mouth
opening (6%), pain
in the ear (4%), and
swelling in the oral
cavity (4%)
49.2 Female: 19
(38), male: 31
(62)
Vital staining,
toluidine blue
50 Suspicious lesions
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Trakroo and
Colleagues,47
2015
India Department of oral
medicine radiology,
secondary
Investigators selected
patients with
suspicious
premalignant and
malignant lesions,
irrespective of age
and sex. Investigators
selected patients
with oral
premalignant
disorders such as
homogeneous
leukoplakia, speckled
leukoplakia,
verrucous
leukoplakia,
erythroplakia,
tobacco pouch
keratosis, erosive
lichen planus, and
oral carcinoma and
patients with a
history of using
tobacco and related
products and alcohol
consumption.
20-70 Female: 7
(14), male: 43
(86)
Cytologic testing,
brush biopsy
50 Malignant and
premalignant lesions
Nanayakkara and
Colleagues,38
2016
Sri Lanka Unclear Investigators
conducted the study
in 116 patients with
oral leukoplakia
lesions diagnosed
and 76 patients with
suspicious oral
malignancy.
21-95 Female: 43
(22.4), male:
149 (77.6)
Cytologic testing,
spatula
181 Suspicious oral
malignancy and oral
leukoplakia
Nanayakkara and
Colleagues,38
2016
Sri Lanka Unclear Investigators
conducted the study
in 116 patients with
oral leukoplakia
lesions diagnosed
and 76 patients with
suspicious oral
malignancy.
21-95 Female: 43
(22.4), male:
149 (77.6)
Cytologic testing,
Cytobrush
181 Suspicious oral
malignancy and oral
leukoplakia
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Summary of main findings for patients’ values and preferences for the
evaluation of potentially malignant disorders.
STUDY TITLE STUDY DESIGN SETTING AND
POPULATION
FINDINGS
Scott and
Colleagues,80
2009
Barriers and triggers to
seeking help for
potentially malignant
oral symptoms:
implications for
interventions
Cross-sectional
study including
82 participants
(semistructured
interviews)
Newly referred patients older
than 18 years, English
speaking, with potentially
malignant oral mucosal
symptoms (that is, localized
nonrecurring ulcer, localized
persistent oral pain, a white
or red patch, a lump or
swelling in the oral cavity)
(United Kingdom)
“In this study, 53 percent of participants waited 31 days
before seeking help from an HCP, and 37 percent waited
more than 3 months.”
“Participants’ initial interpretation was related to the
decision to seek help, with attribution of symptoms to a
minor, self-correcting condition resulting in
postponement of help seeking. Relatedly, a change in
symptoms or persistence of symptoms was regarded as
an indication that something was wrong and in turn
triggered a visit to an HCP.”
“If ‘at-risk’ individuals are introduced to this ‘3-week rule,’
it would standardize the duration given for symptoms to
resolve. Furthermore, if it were emphasized that HCP’s
want to see any oral change that lasts more than 3
weeks, this may reduce the patients’ concern of wasting
HCP’s time and raise confidence in help seeking.”
“The data suggested that emotions play a role in the
help-seeking process. Previous work has indicated that
fear of consultation (in terms of embarrassment and to
the idea of cancer) may prevent a patient from seeking
help for cancer symptoms (8). This study has indicated
that emotions can also act as a trigger to help seeking.”
Fingeret and
Colleagues,74
2010
Multidimensional
analysis of body image
concerns among newly
diagnosed patients with
oral cavity cancer
Cross-sectional
study including
75 participants
(self-completed
questionnaire)
Patients with newly
diagnosed oral cavity cancer
scheduled to undergo
surgical treatment (United
States)
“Results from the clinical interview indicated that 77% of
participants (N¼58) identified current and/or future
appearance-related concerns. These concerns were
primarily related to impending surgery and involved
future scarring/disfigurement at the surgical site, loss of
teeth, loss of hair, and speech concerns.”
Goodson and
Colleagues,75
2011
(Abstract)
Accuracy and patient
acceptance of brush
cytology for diagnosis of
potentially malignant
lesions and oral cancer
Cross-sectional
study including
22 participants
(method for
collecting data
unclear)
Patients with a malignant or
potentially malignant
disorder in the oral mucosa
(United Kingdom)
“Twenty-two patients recorded their brush biopsy
experience on a VAS scale (0 not satisfied to 10 very
satisfied), with a mean score of 8.8 (range 4–10).”
Rogers and
Colleagues,79
2011
Reasons for delayed
presentation in oral and
oropharyngeal cancer:
the patients’ perspective
Cross-sectional
study including
106 participants
(phone
interviews)
Patients treated for oral and
oropharyngeal squamous cell
carcinoma known to be alive
and disease free (United
Kingdom)
“In the survey patients were asked who they first sought
advice from and who was the first healthcare
professional they contacted, both questions being open-
ended. Patients responded that the first advice they
received came either from family doctors (39%, n ¼ 28),
dentists (34%, n ¼ 24) or family/friends (23%, n ¼ 16)
with three unknown.”
“Patients were asked who they first spoke to about their
symptoms they had noticed. For 41% (16/39) their
spouse or partner (eight wife, five husband, two partner,
one girlfriend) was the first person they spoke with, for
5% (2/39) it was immediate family (one son, one
daughter) and for 15% (6/39) it was a friend (four friend,
one ex-wife, one son’s girlfriend). However 38% (15/39)
said they spoke to nobody about it.”
“Patients suggested that strategies to raise awareness
and early presentation should involve increased public
awareness through media coverage (television
advertisements and programmes, radio, newspaper and
magazine columns) with the use of more drastic visual
aids on posters and leaflets in dental, GP surgeries and
pharmacies so people know what to look out for. There
should be improved Internet resources and an education
strategy that more clearly involves schools.
Also they felt that there needs to be an emphasis
on regular dental or medical check ups, so that
asymptomatic lesions and minor symptoms can be acted
upon earlier. The lay public should be encouraged to
self-examine their mouth whilst tooth brushing and to
speak out about their symptoms as soon as they have
even the slightest concern.”
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Awojobi and
Colleagues,73
2012
Patients’ perceptions of
oral cancer screening in
dental practice: a cross-
sectional study
Cross-sectional
study including
180 participants
(self-completed
questionnaire)
Patients with no previous
history of oral cancer
General dental practices
(United Kingdom)
“Only a minority (1%) reported extreme levels of anxiety,
worry and concern about oral cancer screening.”
“There was a generally positive attitude to screening with
a mean score of 13.04 (95%CI 12.68, 13.41).
Approximately 21% of respondents had very positive
attitudes to being screened obtaining the highest
possible score of 16.”
“Ninety-two percent of respondents indicated that they
would like their Dentists to tell them if their mouths were
being checked for signs of oral cancer.”
“Moreover, 97% said they would like help from their
Dentists to help them reduce their risk of getting oral
cancer.”
Henry and
Colleagues,77
2013
(Abstract)
Myth or reality: are
head and neck cancer
patients at increased
risk for suicidal
thoughts and gestures?
Preliminary results
Cross-sectional
study including
46 participants
(self- reported
questionnaire)
Forty-six patients with newly
diagnosed head and neck
cancer completed both
baseline and 3-month follow-
up measures (Canada)
“Lifetime pre-cancer and 3 months suicidal ideations
were 10.8% and 8.5%, respectively; suicidal attempts
were 2.4% and 0%; and 2.2% committed suicide <3
months (during the course of treatment). Suicidal
thoughts at 3 months were related to: lifetime pre-HNC
suicidal ideations (p ¼ 0.034) or past psychiatric
diagnosis (p ¼0.001), higher levels of anxiety/depression
(p ¼0.001) and body image concerns (p ¼ 0.001), lower
quality of life functionally (p ¼ 0.0009) and for H&N-
specific issues (p ¼ 0.01; especially difficulties breathing
p ¼ 0.001, alcohol p ¼ 0.002, pain in mouth/throat/neck
p ¼ 0.01).”
“Suicidal ideations found in our study were significantly
higher than those found in the general population (1
year: men 1.8%; women 2%).”
Karbach and
Colleagues,78
2014
Oral health-related
quality of life of patients
with oral lichen planus,
oral leukoplakia, or oral
squamous cell
carcinoma
Cross-sectional
study including
154 participants
(self- reported
questionnaire)
Consecutive new patients
with a clinical diagnosis of
oral lichen planus, oral
leukoplakia, or oral
squamous cell carcinoma
(Germany)
“A trend toward a difference among the 3 groups was
observed after comparing the total OHIP-G 14 score (P ¼
.086). Patients with OL (7.0 þ/- 10.2) showed the lowest
total OHIP-G 14 scores, patients with OLP (9.4 þ/- 11.4)
showed the highest total OHIP-G 14 scores, and patients
with OSCC (8.8 þ/- 8.6) registered scores between those
of patients with OL and patients with OLP.”
Paudyal and
Colleagues,71
2014
A systematic review of
patient acceptance of
screening for oral
cancer outside of dental
care settings
Systematic
review including
12 studies
Studies reporting
acceptability of oral cancer
screening to people without
a diagnosis (United Kingdom,
United States, Canada, India)
Preference for care provision
“Three studies evaluated patients’ preferences for care
provision for oral cancer screening [34–36]. In all three
studies, participants stated their preference for having
primary care physicians perform the oral cancer
examination. General practice was seen as an
appropriate setting for screening due to its local nature,
ease of access, familiarity and relevance for a health-
related intervention [34,36]. Participants stated their
preference for receiving information about oral cancer
through personal interaction with their primary care
practitioners [34]. Lack of trust towards dentists was
stated as a barrier in one study where participants
perceived a dentist as a ‘tooth specialist’, rather than a
‘mouth specialist’, who lacked the power of a doctor to
make referrals and write prescriptions [34].”
Paudyal and
Colleagues,71
2014
A systematic review of
patient acceptance of
screening for oral
cancer outside of dental
care settings
Systematic
review including
12 studies
Studies reporting
acceptability of oral cancer
screening to people without
a diagnosis (United Kingdom,
United States, Canada, India)
Cost and related factors
“Financial cost was perceived as an influencing factor for
the acceptance of screening. In Dodd et al. [35],
willingness to accept a free oral cancer examination was
high among males (100%; n ¼ 32) whereas younger
females did not uniformly agree with the idea. The
females in the study stated that they would decline the
opportunity to be screened even if screening was
conducted at their worksite and offered free. Participants
in another focus group study also perceived that the
screening should be cost free and speedy [34]. However,
there were stark differences in participants’
characteristics, cultural beliefs regarding oral cancer, and
health care provision across these two studies conducted
in different countries, which may have affected
participants’ opinion about the financial cost related to
screening.”
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Paudyal and
Colleagues,71
2014
A systematic review of
patient acceptance of
screening for oral
cancer outside of dental
care settings
Systematic
review including
12 studies
Studies reporting
acceptability of oral cancer
screening to people without
a diagnosis (United Kingdom,
United States, Canada, India)
Anxiety related to symptom and screening
procedure
“Patients perceived that knowing more about oral cancer
may make them more anxious should they notice any
disease symptom [36]. However, studies aimed at
increasing knowledge and awareness of oral cancer
reported that access to information does not increase
pre-procedural fear and anxiety of participants [31–33].
One study reported that information leaflets did not
change concerns regarding MSE, although one-to-one
interaction sessions were helpful in reducing MSE related
anxiety [31]. Similar results were reported in other
studies where anxiety associated with the screening was
not influenced by leaflet access [33], or were reduced
[32]. One study reported pre-procedural anxiety in one
third of participants (31%), however, on completion of
the screening, there was almost unanimous agreement
that the procedure was painless [30].”
Paudyal and
Colleagues,71
2014
A systematic review of
patient acceptance of
screening for oral
cancer outside of dental
care settings
Systematic
review including
12 studies
Studies reporting
acceptability of oral cancer
screening to people without
a diagnosis (United Kingdom,
United States, Canada, India)
Impact of intervention on compliance of screening
“In one study conducted among a high-risk population in
India [26], compliance with instructions to perform MSE
following access to an information leaflet was high, with
87% of the participants practising MSE and 95%
believing that early detection could improve the chances
of cure. Whilst the sensitivity of MSE was very low at 18%,
the specificity was high at 99.9% (PPV ¼ 72%, NPV ¼
99%). In another study, participants underwent an oral
examination by their dentist and then performed MSE
after reading an instructive leaflet [28]. The study found
that half of the participants (51%) correctly diagnosed
the symptoms and the majority (74%) of participants
found MSE easy to perform. However, the sensitivity and
specificity of MSE was 33% (95% CI 11–65%) and 17%
(95% CI, 6–40%) respectively.”
Paudyal and
Colleagues,71
2014
A systematic review of
patient acceptance of
screening for oral
cancer outside of dental
care settings
Systematic
review including
12 studies
Studies reporting
acceptability of oral cancer
screening to people without
a diagnosis (United Kingdom,
United States, Canada, India)
Patient experiences and acceptance of specific
screening activities
“The acceptance of oral visual examinations (OVE)
conducted in community screening programmes varied
across studies. In a study conducted among tobacco
users in India, overall acceptance and satisfaction levels
of OVE in a mobile setting were encouraging, with 98%
of the participants feeling comfortable with oral
screening tests [27]. Similarly another study in Canada
also reported high acceptance of OVE (98%) among
high-risk individuals (based on risk factors, lack of access
to care, and the high frequency of oral mucosal
anomalies), but, acceptance of biopsy for abnormal
findings and follow-up was low with only 12 out of 31
(39%) patients with clinical leukoplakia accepting the
biopsy [29]. In contrast, a study from South Africa,
reported poor acceptance of OVE conducted in mobile
clinics with only 4.9% (out of the 1320 eligible adults in
the community) accepting a screen during the 6-week
period [34].
Of those who accepted the examination, only 12% were
high-risk participants (specified as men older than 40
years of age).” “Feaver et al. [30] found that the use of
Orascreen (a screen using toluidine blue dye) in aiding
the screening for oral cancer was highly acceptable to
patients; 100% individuals accepted the screening, 83%
described screening as ‘a comfortable experience’ and
95% of the respondents expressed a willingness take
part in future oral health screening.”
ORIGINAL CONTRIBUTIONS
JADA 148(11) http://jada.ada.org November 2017 813.e32
eTABLE 5 (CONTINUED)
STUDY TITLE STUDY DESIGN SETTING AND
POPULATION
FINDINGS
Allen and
Farah,72 2015
Patient perspectives of
diagnostic delay for
suspicious oral mucosal
lesions
Cross-sectional
study including
85 participants
(self-completed
questionnaire)
Patients referred for
suspicious oral mucosal
lesion (leukoplakia,
erythroplakia or
erythroleukoplakia)
Private oral medicine clinic
(Australia)
“Patients had a median of 20 days and a mean of 28.7
days between referral to first visit at a specialist.”
“Patients who reported feeling anxious were asked to
give reasons for feeling anxious and the most common
reason was fear of detection.”
Hassona and
Colleagues,76
2015
Mouth cancer
awareness and beliefs
among dental patients
Cross-sectional
study including
1,200
participants
(close-ended
questionnaire)
Patients attending dental
clinics for examination and
dental treatment (hospital
based)
Patients with a diagnosis of
oral cancer or referred for
assessment of a suspicious
oral mucosal lesion
(Jordan)
“86.1% [of the participants] believed that regular dental
visits can help in the early detection of oral cancer and
67.5% thought that dentists are qualified to diagnose
oral cancer.”
“When asked about actions that they would take if they
noticed an oral lesion, 39.9% stated that they would
consult a dentist, 26.8% that they would consult a
physician, 17.9% that they would apply home remedies
(olive oil, sesame paste, water and salt, mouth wash, or
iodine), and 7.3% would take no action (‘wait and see’).”
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Assessing the Methodological Quality of Systematic Reviews assessment for:
Walsh and colleagues.5 Clinical assessment to screen for the detection of oral
cavity cancer and potentially malignant disorders in apparently healthy adults.
Cochrane Database Syst Rev. 2013;11:CD010173.*
1. Was an ’a priori’ design provided?
The research question and inclusion criteria should be established before the conduct of the review.
Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”
x Yes
, No
, Can’t answer
, Not applicable
2. Was there duplicate study selection and data extraction?
There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.
Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.
x Yes
, No
, Can’t answer
, Not applicable
3. Was a comprehensive literature search performed?
At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE).
Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented
by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the
references in the studies found.
Note: If at least 2 sources þ one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature
search counts as supplementary).
x Yes
, No
, Can’t answer
, Not applicable
4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they
excluded any reports (from the systematic review), based on their publication status, language etc.
Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations,
conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey,
must specify that they were searching for grey/unpublished lit.
x Yes
, No
, Can’t answer
, Not applicable
5. Was a list of studies (included and excluded) provided?
A list of included and excluded studies should be provided.
Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”
x Yes
, No
, Can’t answer
, Not applicable
6. Were the characteristics of the included studies provided?
In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The
ranges of characteristics in all the studies analyzed, e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other
diseases should be reported.
Note: Acceptable if not in table format as long as they are described as above.
x Yes
, No
, Can’t answer
, Not applicable
7. Was the scientific quality of the included studies assessed and documented?
’A priori’ methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-
blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant.
Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality
items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”;
a summary score/range for all studies is not acceptable).
x Yes
, No
, Can’t answer
, Not applicable
* Source: Shea and colleagues.16
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8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and
explicitly stated in formulating recommendations.
Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes”
for this question if scored “no” for question 7.
x Yes
, No
, Can’t answer
, Not applicable
9. Were the methods used to combine the findings of studies appropriate?
For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for
homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be
taken into consideration (i.e., is it sensible to combine?).
Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability
between interventions.
x Yes
, No
, Can’t answer
, Not applicable
10. Was the likelihood of publication bias assessed?
An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests
(e.g., Egger regression test, Hedges-Olken).
Note: If no test values or funnel plot included, score “no.” Score “yes” if mentions that publication bias could not be assessed because there
were fewer than 10 included studies.
, Yes
, No
, Can’t answer
x Not applicable
11. Was the conflict of interest included?
Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.
Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.
x Yes
, No
, Can’t answer
, Not applicable
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Assessing the Methodological Quality of Systematic Reviews assessment for:
Macey and colleagues.4 Diagnostic tests for oral cancer and potentially
malignant disorders in patients presenting with clinically evident lesions.
Cochrane Database Syst Rev. 2015;5:CD010276.*
1. Was an ’a priori’ design provided?
The research question and inclusion criteria should be established before the conduct of the review.
Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”
x Yes
, No
, Can’t answer
, Not applicable
2. Was there duplicate study selection and data extraction?
There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.
Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.
x Yes
, No
, Can’t answer
, Not applicable
3. Was a comprehensive literature search performed?
At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE).
Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented
by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the
references in the studies found.
Note: If at least 2 sources þ one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature
search counts as supplementary).
x Yes
, No
, Can’t answer
, Not applicable
4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they
excluded any reports (from the systematic review), based on their publication status, language etc.
Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations,
conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey,
must specify that they were searching for grey/unpublished lit.
x Yes
, No
, Can’t answer
, Not applicable
5. Was a list of studies (included and excluded) provided?
A list of included and excluded studies should be provided.
Note: Acceptable if the excluded studies are referenced. If there is an electronic link to
the list but the link is dead, select “no.”
x Yes
, No
, Can’t answer
, Not applicable
6. Were the characteristics of the included studies provided?
In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The
ranges of characteristics in all the studies analyzed, e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other
diseases should be reported.
Note: Acceptable if not in table format as long as they are described as above.
x Yes
, No
, Can’t answer
, Not applicable
7. Was the scientific quality of the included studies assessed and documented?
’A priori’ methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-
blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant.
Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality
items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”;
a summary score/range for all studies is not acceptable).
x Yes
, No
, Can’t answer
, Not applicable
* Source: Shea and colleagues.16
ORIGINAL CONTRIBUTIONS
JADA 148(11) http://jada.ada.org November 2017 813.e36
eTABLE 7 (CONTINUED)
8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and
explicitly stated in formulating recommendations.
Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes”
for this question if scored “no” for question 7.
x Yes
, No
, Can’t answer
, Not applicable
9. Were the methods used to combine the findings of studies appropriate?
For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for
homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be
taken into consideration (i.e., is it sensible to combine?).
Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability
between interventions.
x Yes
, No
, Can’t answer
, Not applicable
10. Was the likelihood of publication bias assessed?
An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests
(e.g., Egger regression test, Hedges-Olken).
Note: If no test values or funnel plot included, score “no.” Score “yes” if mentions that publication bias could not be assessed because there
were fewer than 10 included studies.
, Yes
, No
, Can’t answer
x Not applicable
11. Was the conflict of interest included?
Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.
Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.
x Yes
, No
, Can’t answer
, Not applicable
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Assessing the Methodological Quality of Systematic Reviews assessment for:
Gualtero and Suarez Castillo.23 Biomarkers in saliva for the detection of oral
squamous cell carcinoma and their potential use for early diagnosis: a
systematic review. Acta Odontol Scand. 2016;74(3):170-177.*
1. Was an ’a priori’ design provided?
The research question and inclusion criteria should be established before the conduct of the review.
Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”
x Yes
, No
, Can’t answer
, Not applicable
2. Was there duplicate study selection and data extraction?
There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.
Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.
, Yes
, No
x Can’t answer
, Not applicable
3. Was a comprehensive literature search performed?
At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE).
Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented
by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the
references in the studies found.
Note: If at least 2 sources þ one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature
search counts as supplementary).
, Yes
x No
, Can’t answer
, Not applicable
4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they
excluded any reports (from the systematic review), based on their publication status, language etc.
Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations,
conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey,
must specify that they were searching for grey/unpublished lit.
, Yes
x No
, Can’t answer
, Not applicable
5. Was a list of studies (included and excluded) provided?
A list of included and excluded studies should be provided.
Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”
, Yes
x No
, Can’t answer
, Not applicable
6. Were the characteristics of the included studies provided?
In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The
ranges of characteristics in all the studies analyzed, e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other
diseases should be reported.
Note: Acceptable if not in table format as long as they are described as above.
x Yes
, No
, Can’t answer
, Not applicable
7. Was the scientific quality of the included studies assessed and documented?
’A priori’ methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-
blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant.
Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality
items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”;
a summary score/range for all studies is not acceptable).
x Yes
, No
, Can’t answer
, Not applicable
* Source: Shea and colleagues.16
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8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and
explicitly stated in formulating recommendations.
Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes”
for this question if scored “no” for question 7.
x Yes
, No
, Can’t answer
, Not applicable
9. Were the methods used to combine the findings of studies appropriate?
For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for
homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be
taken into consideration (i.e., is it sensible to combine?).
Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability
between interventions.
, Yes
, No
, Can’t answer
x Not applicable
10. Was the likelihood of publication bias assessed?
An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests
(e.g., Egger regression test, Hedges-Olken).
Note: If no test values or funnel plot included, score “no.” Score “yes” if mentions that publication bias could not be assessed because there
were fewer than 10 included studies.
, Yes
x No
, Can’t answer
, Not applicable
11. Was the conflict of interest included?
Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.
Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.
, Yes
x No
, Can’t answer
, Not applicable
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Assessing the Methodological Quality of Systematic Reviews assessment for:
Stuani and colleagues.23 Salivary biomarkers as tools for oral squamous cell
carcinoma diagnosis: a systematic review. Head Neck. 2017;39(4):797-811.*
1. Was an ’a priori’ design provided?
The research question and inclusion criteria should be established before the conduct of the review.
Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”
x Yes
, No
, Can’t answer
, Not applicable
2. Was there duplicate study selection and data extraction?
There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.
Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.
x Yes
, No
, Can’t answer
, Not applicable
3. Was a comprehensive literature search performed?
At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE).
Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented
by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the
references in the studies found.
Note: If at least 2 sources þ one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature
search counts as supplementary).
x Yes
, No
, Can’t answer
, Not applicable
4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they
excluded any reports (from the systematic review), based on their publication status, language etc.
Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations,
conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey,
must specify that they were searching for grey/unpublished lit.
x Yes
, No
, Can’t answer
, Not applicable
5. Was a list of studies (included and excluded) provided?
A list of included and excluded studies should be provided.
Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”
x Yes
, No
, Can’t answer
, Not applicable
6. Were the characteristics of the included studies provided?
In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The
ranges of characteristics in all the studies analyzed, e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other
diseases should be reported.
Note: Acceptable if not in table format as long as they are described as above.
x Yes
, No
, Can’t answer
, Not applicable
7. Was the scientific quality of the included studies assessed and documented?
’A priori’ methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-
blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant.
Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality
items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”;
a summary score/range for all studies is not acceptable).
x Yes
, No
, Can’t answer
, Not applicable
* Source: Shea and colleagues.16
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8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and
explicitly stated in formulating recommendations.
Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes”
for this question if scored “no” for question 7.
x Yes
, No
, Can’t answer
, Not applicable
9. Were the methods used to combine the findings of studies appropriate?
For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for
homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be
taken into consideration (i.e., is it sensible to combine?).
Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability
between interventions.
, Yes
, No
, Can’t answer
x Not applicable
10. Was the likelihood of publication bias assessed?
An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests
(e.g., Egger regression test, Hedges-Olken).
Note: If no test values or funnel plot included, score “no.” Score “yes” if mentions that publication bias could not be assessed because there
were fewer than 10 included studies.
, Yes
x No
, Can’t answer
, Not applicable
11. Was the conflict of interest included?
Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.
Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.
, Yes
x No
, Can’t answer
, Not applicable
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Additional study characteristics of included studies.
STUDY INDEX TEST* POSITIVITY THRESHOLD
(INDEX TEST)
POSITIVITY THRESHOLD
(CRITERION TEST)
CONFLICTS OF INTEREST
AND SOURCE OF FUNDING
Mashberg,55 1980 Vital staining, toluidine blue “Positive for malignancy if the
lesion stains dark blue (royal
or navy); either the entire
lesion or a portion of it may
stain solidly or stippled.
Occasional equivocal stains
are considered positive unless
proven otherwise.”
All dysplasia is positive. Not reported
Silverman and
Colleagues,58
1984
Vital staining, toluidine blue Dye uptake was considered
positive
All dysplasia is positive. Not reported
Warnakulasuriya
and Johnson,60
1996
Vital staining, OraScan
toluidine blue
Any dye retention classified as
positive
All dysplasia is positive. KASSW supported by Dunhill
Medical Trust Consumables in
project funded by Zila
Pharmaceuticals
Onizawa and
Colleagues,29
1999
Autofluorescence,
fluorescence photography
with ultraviolet flash
“The autofluorescence of the
lesions was judged according
to the intensity of fluorescence
depicted on the films. Lesions
with red or pink fluorescence
under the SC-39 filter, and
those with red or orange
fluorescence under the SC-52
or -48 filter were defined as
positive, whereas lesions
without these colors of
fluorescence were defined as
negative.”
All dysplasia is positive. Not reported
Sciubba,44 1999 Cytologic testing, OralCDx Negative: no epithelial
abnormality; atypical:
abnormal epithelial changes
of uncertain diagnostic
significance; positive:
definitive cellular evidence
of epithelial dysplasia or
carcinoma; inadequate:
incomplete transepithelial
biopsy specimens (these
specimens were excluded
from the study); atypical cases
included as positive
All dysplasia is positive. Funded by OralScan
Laboratories, which produces
OralCDx products
Onofre and
Colleagues,57
2001
Vital staining, toluidine blue Followed recommendations of
Mashberg (Mashberg 1980,†:
- “inadequate cell count”
- “negative”
- “atypical epithelial cells”
- “positive for dysplasia or
OSCC”
Atypical and positive results
recorded as positive; inade-
quate results excluded
All dysplasia is positive. “We are indebted to the Mario
A.S. Paino Laboratory of
Clinical Pathology.”
Svirsky and
Colleagues,46
2002
Cytologic testing, OralCDx Stated no conflict of interests,
declaration of some funding
from OralCDx, but
involvement of OralCDx
laboratories is stated for
retrospective analysis; unclear
whether there were any
atypical results
All dysplasia is positive. Declaration of some funding
from OralCDx, but
involvement of OralCDx
laboratories is stated for
retrospective analysis
Cheng and
Yang,53 2003a
Vital staining, Oratest rinse Blue staining of the lesion
predicts a positive outcome;
blurred blue staining, which
could not be washed out by
the mouthwash fluid, was also
considered positive
Unclear Not reported
* We compared all index tests against biopsy results as the criterion standard.
† Source: Mashberg 1980.55
‡ Source: Sciubba 1999.44
ORIGINAL CONTRIBUTIONS
JADA 148(11) http://jada.ada.org November 2017 813.e42
eTABLE 10 (CONTINUED)
STUDY INDEX TEST* POSITIVITY THRESHOLD
(INDEX TEST)
POSITIVITY THRESHOLD
(CRITERION TEST)
CONFLICTS OF INTEREST
AND SOURCE OF FUNDING
Cheng and
Yang,53 2003b
Vital staining, Oratest stain Blue staining of the lesion
predicts a positive outcome;
blurred blue staining, which
could not be washed out by
the mouthwash fluid, was also
considered positive
Unclear Not reported
Navone and
Colleagues,39
2004
Cytologic testing, Cytobrush Not reported 1 atypical result
but unclear how it was
classified
Unclear Not reported
Scheifele and
Colleagues,43
2004
Cytologic testing, OralCDx Based on previous study
(Sciubba 1999‡):
- “inadequate cell count”
- “negative”
- “atypical epithelial cells”
- “positive for dysplasia or
OSCC”
All dysplasia is positive. “OralCDx test kits and OralCDx
analyses for this study were
provided by the German
OralCDx centre.Germany.”
Chen and
Colleagues,52
2007
Vital staining, methylene blue Unclear All dysplasia is positive. “Grant supported by NSC-94-
2314B075 and VGH94242C”
Du and
Colleagues,54
2007
Vital staining, rose bengal “Staining result of a lesion was
classified as 1, 2, 3 or 4
according to the shade tabs. In
the present study, staining
results of 3 and 4 were
regarded as RB positive
staining, while staining results
of 1 and 2 were regarded as
RB negative staining.”
All dysplasia is positive. “Grant sponsor: Science and
Technology Bureau of Wuhan
City, People’s Republic of
China; Grant number:
20026002084.”
Farah and
McCullough,63
2007
Tissue reflectance, ViziLite Unclear; although the authors
state that all lesions appeared
“aceto-white” under
chemiluminescent light and
that they considered them
“ViziLite positive,” it is not clear
that this detail was used in the
diagnostic decision
Unclear None
Gupta and
Colleagues,70
2007
Cytologic testing and vital
staining, toluidine blue and
brush cytologic testing
Participants’ results classed as
positive or negative but no
thresholds or inadequate or
equivocal results reported. The
authors analyzed the following
parameters in the smear:
enlarged nuclei, variation in
nuclear size and shape
(pleomorphism), nuclear
borders, nuclear-to-
cytoplasmic ratio, number of
nuclei, hyperchromatism,
chromatin pattern and
distribution, and discrepancy
in maturation.
All dysplasia is positive. Not reported
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STUDY INDEX TEST* POSITIVITY THRESHOLD
(INDEX TEST)
POSITIVITY THRESHOLD
(CRITERION TEST)
CONFLICTS OF INTEREST
AND SOURCE OF FUNDING
Epstein and
Colleagues,67
2008
Tissue reflectance and vital
staining, ViziLite and toluidine
blue
“The investigator reported
their subjective assessment of
the impact of
chemiluminescence upon
lesions characteristics of
brightness, sharpness, surface
texture, and/or size using a
four point Likert scale
(decreased, no change, slight
improvement, marked
improvement). After the
toluidine blue staining the
investigator recorded the
staining pattern either as
negative, incomplete, or
complete total lesion staining.”
Potential confusion over
“incomplete.” Sequence of
tests: visual, light based, vital
stain, then criterion standard
Mild and moderate dysplasia
classified as negative and
severe dysplasia classified as
positive This was reclassified
to include all dysplasia as
biopsy positive.
Funded by Trylon Corp Inc.,
authors linked to Zila Inc.
Mehrotra and
Colleagues,37
2008
Cytologic testing, baby
toothbrush
Investigators categorized cells
showing changes as
malignant: “enlarged nuclei,
variation in nuclear size and
shape (pleomorphism),
nuclear borders,
nucleo:cytoplasmic ratio,
number of nuclei,
binucleation, keratinization,
tadpole forms, and
hyperchromatism chromatin”
No atypical results reported
All dysplasia is positive. Not discussed
Navone and
Colleagues,40
2008
Cytologic testing, curette “The diagnosis of dysplasia or
carcinoma was based on
recognized WHO criteria. The
diagnosis was recorded as
either negative or positive for
the presence of neoplasia or
dysplasia, whatever the
grade.”
Atypical results not reported
All dysplasia is positive. “This study has been
supported in part by MURST
ex-60% Universita‘ di Torino’,
Ricerca Finalizzata Regione
Piemonte’ and by a grant of
Compagnia di San Paolo
Programma Oncologia’,
Torino, Italy.”
Allegra and
Colleagues,48
2009
Vital staining, toluidine blue “Lesions that showed dark
blue staining were considered
to be positive for premalignant
or malignant tissue, while
those with light staining, or
totally not coloured, were
considered negative.”
All dysplasia is positive. Not reported
McIntosh and
Colleagues,64
2009
Tissue reflectance, Microlux “After rinsing with the acetic
acid solution, the
manufacturer states that
irregular cells will take on a
whitish hue which will contrast
with the surrounding tissues
making it more obvious to the
examiner.” “Borders were
designated either as diffuse or
sharp.”
All dysplasia is positive. None
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STUDY INDEX TEST* POSITIVITY THRESHOLD
(INDEX TEST)
POSITIVITY THRESHOLD
(CRITERION TEST)
CONFLICTS OF INTEREST
AND SOURCE OF FUNDING
Delavarian and
Colleagues,32
2010
Cytologic testing, OralCDx Investigators categorized the
pathologic findings into 3
groups: positive, dysplastic
epithelial changes; negative,
absence of any evidence
suggesting dysplasia;
inadequate sampling, no
atypical results reported.
All dysplasia is positive. University support
acknowledged
Mehrotra and
Colleagues,28
2010
Autofluorescence, VELscope Normal mucosa (a negative
VELscope finding) appears as a
bright green glow, whereas
abnormal mucosa (a positive
VELscope finding) is identified
by a loss of fluorescence and
appears dark.
Unclear None
Mehrotra and
Colleagues,28
2010
Tissue reflectance and vital
staining, ViziLite Plus
A positive ViziLite finding
appeared aceto-white. The
ViziLite Plus with TBlue system
also contains a toluidine blue
dye, which is intended to be
used only to mark lesions that
are positive according to the
ViziLite screening for follow-up
examination.
Unclear None
Nagaraju and
Colleagues,56
2010
Vital staining, toluidine blue
and Lugol iodine
For either or both of the tests,
staining results were positive.
All dysplasia is positive. Not reported
Awan 2011a24 Autofluorescence, VELscope “The possible outcome of the
autofluorescence examination
was determined by the
manufacturer’s literature i.e.
FVL–fluorescence visualization
loss, FVR–fluorescence
visualization retained and FVI–
fluorescence visualization
increased. Both examiners
were calibrated by an
experienced professional
from the LED Diagnostics
(the manufacturer).”
All dysplasia is positive. “We thank Dr. Connie Yang for
assistance in setting up the
data entry system and Dr.
Derek Cooper for the data
analysis. VELscope system for
the study was supplied by LED
Diagnostics.”
Awan 2011b66 Tissue reflectance, ViziLite Aceto-white ¼ positive;
Normal illumination ¼
negative
All dysplasia is positive. “We thank Dr. Connie Yang for
assistance in setting up the
data entry system and Dr.
Derek Cooper for the data
analysis. VELscope system for
the study was supplied by LED
Diagnostics.”
Cancela-
Rodriguez and
Colleagues,50
2011
Vital staining, toluidine blue “The stain was considered
positive when the surface
mucosa took on a blue colour,
either if the entire lesion was
stained or just a portion of it.
Those that do not take
colouration or with equivocal
findings were considered
negatives.”
All dysplasia is positive. Not reported
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STUDY INDEX TEST* POSITIVITY THRESHOLD
(INDEX TEST)
POSITIVITY THRESHOLD
(CRITERION TEST)
CONFLICTS OF INTEREST
AND SOURCE OF FUNDING
Guneri and
Colleagues,69
2011
Cytologic testing and vital
staining, toluidine blue and
Cytobrush
“The pattern of dye retention
and the intensity of stain
retention were recorded (2,
dark blue staining; 1, minimal
blue staining; 0, no blue
staining). Occasionally, normal
mucosa also appeared light
blue, but this staining was not
interpreted as positive.”
Sequence of tests: staining,
brush biopsy, followed by
criterion standard
Mild and moderate dysplasia
classified as negative and
severe dysplasia and
carcinoma in situ classified as
positive
“The study was funded by Ege
University Scientific Research
Projects Fund (2005-DIS-
014).”
Koch 2011a35 Cytologic testing, Cytobrush
Plus GT
All dysplasia is positive. No
atypical results reported.
All dysplasia is positive. Not reported
Koch 2011b27 Autofluorescence: “Two
different investigation
methods were applied: the
standard examination by
white light and the
examination by a 400-nm
wavelength light source that is
supposed to trigger a green
light emission (>500 mm) in
normal mucosa.” Documented
with digital reflex photography
Positivity threshold: “SCC, and
dysplasia [identified]
depending on two different
autofluorescence features:
(1) A black or dark green
aspect, as well as red
indicating dysplasia or SCC
(positive). Also, a speckled,
heterotopic aspect of both
green and autofluorescence
negative or reddish regions
indicated a positive finding
(2) The presence of red
mucosal autofluorescence was
evaluated as a separate
indicator for dysplasia or SCC
(positive).”
All dysplasia is positive. None
Mehrotra and
Colleagues,36
2011
Cytologic testing, OralCDx Three categories: negative, no
epithelial abnormality;
atypical, abnormal epithelial
changes; positive definitive
evidence of epithelial
dysplasia or carcinoma
Atypical results considered
positive
Unclear None
Scheer and
Colleagues,31
2011
Autofluorescence, VELscope “The complete loss of the
normal tissue fluorescence
(fluorescence visualization loss
[FVL]) was rated as malignant
or dysplastic alteration. Red or
orange fluorescence was not
considered as malignant.”
All dysplasia is positive. Not reported
Upadhyay and
Colleagues,59
2011
Vital staining, toluidine blue Used Mashberg levels55:
“doubtful light blue stain was
considered as positive until
biopsy proves the contrary”
All dysplasia is positive. No conflicts
Awan and
Colleagues,49
2012
Vital staining, toluidine blue “Among the test group (n ¼
82), 46 (56.1%) were positive
for TBlue as they retained the
dye. An almost equal number
did not retain TBlue and
therefore were recorded as
negative for the test.”
All dysplasia is positive. “This study did not receive any
grant funding by the industry
but the test kits were supplied
free of charge by Zila Inc.”
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STUDY INDEX TEST* POSITIVITY THRESHOLD
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POSITIVITY THRESHOLD
(CRITERION TEST)
CONFLICTS OF INTEREST
AND SOURCE OF FUNDING
Farah and
Colleagues,25
2012
Autofluorescence, VELscope “Lesions that showed loss of
autofluorescence were
deemed positive, and lesions
that did not show any loss of
autofluorescence were
deemed negative. In addition,
all lesions that lost
autofluorescence were
blanched to evaluate diascopic
fluorescence, and those that
were deemed negative for loss
of autofluorescence only if
complete blanching was
achieved.”
Unclear Not reported
Mojsa and
Colleagues,68
2012
Tissue reflectance and vital
staining, ViziLite Plus
“Chemiluminescence
examination including the
brightness, sharpness, surface
texture, and size of the lesion
using a 4-point scale
(decreased, no change, slight
improvement, marked
improvement)” “Tolonium
chloride examination
including the staining pattern
using a 3-point scale
(negative, incomplete,
complete)” Not clear which
level of coloration equates to
negative, incomplete, or
positive
All dysplasia is positive. Not reported
Ng and
Colleagues,41
2012
Cytologic testing, Oral Advance “The histopathologic diagnosis
was classified into 4 groups
according to the presence and
the degree of epithelial
dysplasia, as summarized in
Table II: benign, low-risk PMD,
high-risk PMD, and SCC.”
Atypical results not reported
All dysplasia is positive. Not reported
Rahman and
Colleagues,42
2012
Vital staining, Cytobrush Unclear Mild dysplasia classified as
negative and moderate and
severe dysplasia classified as
positive
Not reported
Rahman and
Colleagues,42
2012
Cytologic testing, Cytobrush Unclear; atypical results
considered positive
Mild dysplasia classified as
negative and moderate and
severe dysplasia classified as
positive
Not reported
Seijas-Naya and
Colleagues,45
2012
Cytologic testing, OralCDx “Positive for presence of
dysplasia or carcinoma. All
categories are atypical (cellular
changes of uncertain
diagnosis), positive for
dysplasia or carcinoma,
negative (normal cells) and
inappropriate (incomplete
transepithelial sample).”
Unclear whether atypical
results were considered
positive or negative
All dysplasia is positive. Not reported
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STUDY INDEX TEST* POSITIVITY THRESHOLD
(INDEX TEST)
POSITIVITY THRESHOLD
(CRITERION TEST)
CONFLICTS OF INTEREST
AND SOURCE OF FUNDING
Ujaoney and
Colleagues,65
2012
Tissue reflectance and vital
staining, ViziLite Plus
“Dark staining lesions were
considered positive; faint
lesions were considered
equivocal; and those which
did not take up the stain were
considered negative. Using
these categories, lesions were
classified as TBLU-positive if it
was observed to be positive
and TBLU-negative if the result
was either equivocal or
negative..The lesions that
reflected the blue-white light
were considered CHEM-
positive. Any new lesion, not
visible during conventional
visual examination under
incandescent light, but visible
after chemiluminescent
illumination test was noted
and documented.” “We
considered a lesion to be
CHTB-positive if it was both
CHEM-positive and TBLU-
positive; otherwise the lesion
was considered to be CHTB-
negative.”
Moderate and severe or
carcinoma classified as
positive and mild dysplasia
classified as negative
None
Ujaoney and
Colleagues,65
2012
Tissue reflectance, ViziLite “The lesions that reflected the
blue-white light were
considered CHEM-positive.
Any new lesion, not visible
during conventional visual
examination under
incandescent light, but visible
after chemiluminescent
illumination test was noted
and documented.”
Moderate and severe or
carcinoma classified as
positive and mild dysplasia
classified as negative
None
Chaudhari and
Colleagues,51
2013
Vital staining, toluidine blue Unclear All dysplasia is positive. Not reported
Chaudhari and
Colleagues,51
2013
Vital staining, Lugol iodine Unclear All dysplasia is positive. Not reported
Fontes and
Colleagues,33
2013
Cytologic testing, Cytobrush Squamous cell carcinoma,
carcinoma, malignancy
suggestive of squamous cell
carcinoma, and epithelial
dysplasia considered positive
Atypical results considered
negative but unclear the
proportion of lesions that were
atypical
All dysplasia is positive. “This study was supported by
grants from Coordenação de
Aperfeiçoamento de Pessoal
de Nível Superior (CAPES), a
Brazilian governmental
institution. The authors certify
that they have no commercial
or associative interest that
represents a conflict of interest
in connection with the
manuscript.”
Hanken and
Colleagues,26
2013
Autofluorescence, VELscope “According to the existing
literature, the complete loss of
the normal tissue fluorescence
(fluorescence visualization
loss) was rated as malignant
or dysplastic. A fluorescence in
red or orange was not rated as
malignant according to the
literature [11,14].”
All dysplasia is positive. None
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eTABLE 10 (CONTINUED)
STUDY INDEX TEST* POSITIVITY THRESHOLD
(INDEX TEST)
POSITIVITY THRESHOLD
(CRITERION TEST)
CONFLICTS OF INTEREST
AND SOURCE OF FUNDING
Kammerer and
Colleagues,34
2013
Cytologic testing, Cytobrush
Plus GT
“‘Negative’ in cases with
benign changes or with the
finding of mild dysplastic
epithelial cells (SIN 1) only,17,
20, 35 and as ‘positive’ if cells
with moderate or severe
dysplasia (SIN 2, SIN 3) or
malignant tumor cells.” No
atypical results reported
Moderate and severe
dysplasia classified as positive
and mild dysplasia classified
as negative
None
Petruzzi and
Colleagues,30
2014
Autofluorescence, VELscope “According to the literature,
the loss of the normal tissue
fluorescence was judged as a
malignant or dysplastic
alteration. Red or orange
fluorescence was not
considered as malignant
according to the literature.”
All dysplasia is positive. None
Chainani-Wu and
Colleagues,62
2015
Tissue reflectance, ViziLite Investigators described ViziLite
examination results that
demonstrated increased
brightness in comparison with
the visual examination results
as ViziLite positive.
Severe and squamous cell
carcinoma are positive and
mild and moderate dysplasia
classified as negative
Not reported
Chainani-Wu and
Colleagues,62
2015
Tissue reflectance and vital
staining, ViziLite and toluidine
blue
Unclear Severe and squamous cell
carcinoma are positive and
mild and moderate dysplasia
classified as negative
Not reported
Singh and
Shukla,6 2015
Vital staining, toluidine blue “A dark blue (royal or navy)
stain is considered positive if
either the entire lesion being
stained or a portion of it is
stained or stippled (Figs. 1, 2).
A light blue staining is
considered doubtful. If there is
no colour absorbed by the
lesion, it is taken as a negative
stain.”
All dysplasia is negative. Not reported
Trakroo and
Colleagues,47
2015
Cytologic testing, brush biopsy All dysplasia positive. Atypical
results included but unclear
whether they are classified as
negative or positive
All dysplasia is positive. None
Nanayakkara and
Colleagues,38
2016
Cytologic testing, spatula Mild dyskaryosis, moderate
dyskaryosis, severe
dyskaryosis, and malignancy
classified as positive
No atypical results reported
All dysplasia is positive. Not reported
Nanayakkara and
Colleagues,38
2016
Cytologic testing, Cytobrush Mild dyskaryosis, moderate
dyskaryosis, severe
dyskaryosis, and malignancy
classified as positive
No atypical results reported
All dysplasia is positive. None
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Vital staining adjuncts to evaluate clinically evident, suspicious lesions.
VITAL STAINING SENSITIVITY 95% CI* SPECIFICITY 95% CI POSITIVE
LIKELIHOOD
RATIO
95% CI NEGATIVE
LIKELIHOOD
RATIO
95% CI
With Verification
Bias†
0.87 0.80 to 0.94 0.71 0.61 to 0.92 3.04 2.06 to 4.48 0.18 0.10 to 0.32
Verification Bias
Minimized‡
0.87 0.79 to 0.95 0.7 0.59 to 0.82 2.92 1.95 to 4.8 0.19 0.10 to 0.36
* CI: Confidence interval.
† We calculated the estimates with data from the following studies: Allegra and colleagues48 2009, Awan and colleagues49 2012, Cancela-Rodriguez
and colleagues50 2011, Chen and colleagues52 2007, Cheng and Yang53 2003, Du and colleagues54 2007, Mashberg55 1980, Nagaraju and col-
leagues56 2010, Onofre and colleagues57 2001, Rahman and colleagues42 2012, Silverman and colleagues58 1984, Upadhyay and colleagues59
2011, Warnakulasuriya and Johnson60 1996, Chaudhari and colleagues51 2013, and Singh and Shukla61 2015.
‡ We calculated the estimates with data from the following studies: Allegra and colleagues48 2009, Awan and colleagues49 2012, Cancela-Rodriguez
and colleagues50 2011, Chen and colleagues52 2007, Cheng and Yang53 2003, Du and colleagues54 2007, Mashberg55 1980, Nagaraju and col-
leagues56 2010, Onofre and colleagues57 2001, Rahman and colleagues42 2012, Silverman and colleagues58 1984, Upadhyay and colleagues59
2011, Warnakulasuriya and Johnson60 1996, and Singh and Shukla61 2015.
eTABLE 12
Cytologic adjuncts to evaluate clinically evident, suspicious lesions.
CYTOLOGIC
TESTING
SENSITIVITY 95% CI* SPECIFICITY 95% CI POSITIVE
LIKELIHOOD
RATIO
95% CI NEGATIVE
LIKELIHOOD
RATIO
95% CI
With Verification
Bias†
0.92 0.86 to 0.98 0.94 0.88 to 0.99 14.18 5.82 to 34.59 0.08 0.04 to
0.18
Verification Bias
Minimized‡
0.93 0.86 to 0.99 0.94 0.90 to 0.98 16.14 8.15 to 31.94 0.08 0.03 to
0.20
* CI: Confidence interval.
† We calculated the estimates with data from the following studies: Delavarian and colleagues32 2010, Koch and colleagues35 2011a, Mehrotra and
colleagues37 2008, Navone and colleagues39 2004, Navone and colleagues40 2008, Ng and colleagues41 2012, Rahman and colleagues42 2012,
Sciubba44 1999, Seijas-Naya and colleagues45 2012, Svirsky and colleagues46 2002, Fontes and colleagues33 2013, Kammerer and colleagues34
2013, Nanayakkara and colleagues38 2016, Trakroo and colleagues47 2015, and Scheifele and colleagues43 2004.
‡ We calculated the estimates with data from the following studies: Delavarian and colleagues32 2010, Koch and colleagues35 2011a, Mehrotra and
colleagues37 2008, Navone and colleagues40 2008, Ng and colleagues41 2012, Rahman and colleagues42 2012, Sciubba44 1999, Fontes and col-
leagues33 2013, Kammerer and colleagues34 2013, Nanayakkara and colleagues38 2016, Trakroo and colleagues47 2015, and Scheifele and
colleagues43 2004.
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eTABLE 13
Vital staining adjuncts to evaluate clinically evident, suspicious lesions
(verification bias minimized?)*
TEST RESULT EFFECT PER 100,000 PATIENTS TESTED, NO. (RANGE)
(95% CONFIDENCE INTERVAL [CI])
NO. OF
PARTICIPANTS
(STUDIES)
QUALITY
OF THE
EVIDENCE
(GRADE)§
COMMENTS
Prevalence 0.25%† Prevalence 2.0%‡
True-Positive
Results (Patients
Needing Biopsy)
217 (198 to 238) 1,740 (1,580 to 1,900)
1,289 (14) Low¶,#,**
Patients will be identified correctly as
having a potentially malignant or
malignant disorder, and timely
referral to a specialist or biopsy will
be performed.
False-Negative
Results (Patients
Incorrectly
Classified as Not
Needing Biopsy)
33 (12 to 52) 260 (100 to 420) An appropriate diagnosis would be
missed, worsening the prognosis of
the disease.
True-Negative
Results (Patients
Without Need for
Biopsy)
69,825 (58,853 to 81,795) 68,600 (57,820 to 80,360)
1,289 (14) Low¶,#,**
Patients will receive reassurance that
they do not have a potentially
malignant or malignant disorder.
False-Positive
Results (Patients
Incorrectly
Classified as
Needing Biopsy)
29,925 (17,955 to 40,897) 29,400 (17,640 to 40,180) Patients would be identified
incorrectly as having a potentially
malignant or malignant disorder and
would undergo additional
unnecessary testing and biopsy.
* Setting: Primary care. Pooled sensitivity: 0.87 (95% confidence interval, 0.79 to 0.95). Pooled specificity: 0.70 (95% confidence interval, 0.59 to
0.82). Positive likelihood ratio, 2.92 (95% confidence interval, 1.95 to 4.38); negative likelihood ratio, 0.19; (95% confidence interval, 0.10 to 0.36).
Sources: Allegra and colleagues48 2009, Awan and colleagues49 2012, Cancela-Rodriguez and colleagues50 2011, Chen and colleagues52 2007,
Cheng and Yang53 2003, Du and colleagues54 2007, Mashberg55 1980, Nagaraju and colleagues56 2010, Onofre and colleagues57 2001, Rahman
and colleagues42 2012, Silverman and colleagues58 1984, Upadhyay and colleagues59 2011, Warnakulasuriya and Johnson60 1996, and Singh and
Shukla61 2015.
† We estimated the prevalence by using data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program (300,682
people living with oral cavity and pharynx cancer in the United States in 2013) and the 2010 census data for adults 45 years or older collected by the
US Census Bureau.
‡ The panel provided illustrative prevalence as an estimation of the number of histopathologic diagnoses from dysplasia to cancer.
§ GRADE: Grading of Recommendations Assessment, Development and Evaluation.
¶ Patient selection and exclusion from analysis were inappropriate. Poor-quality reporting did not provide sufficient information to judge key domains
for risk of bias.
# Investigators conducted most studies in secondary and tertiary care settings. Most patients had a higher probability of having a malignant or
potentially malignant disorder.
** The positivity threshold for the criterion standard included from mild dysplasia to cancer in all studies except for those of Rahman and colleagues
2012, Singh and Shukla 2015, and Cheng and Yang 2003.
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eTABLE 14
Cytologic adjuncts to evaluate clinically evident, suspicious lesions (verification
bias minimized?)*
TEST RESULT EFFECT PER 100,000 PATIENTS TESTED. NO. (RANGE) NO. OF
PARTICIPANTS
(STUDIES)
QUALITY
OF THE
EVIDENCE
(GRADE)§
COMMENTS
Prevalence 0.25%† Prevalence 2.0%‡
True-Positive
Results (Patients
Needing Biopsy)
233 (215 to 248) 1,860 (1,720 to 1,980)
1,748 (12) Moderate¶,#
Patients will be identified correctly
as having a potentially malignant or
malignant disorder, and timely
referral to a specialist or biopsy will
be performed.
False-Negative
Results (Patients
Incorrectly
Classified as Not
Needing Biopsy)
17 (2 to 35) 140 (20 to 280) An appropriate diagnosis would be
missed, worsening the prognosis of
the disease.
True-Negative
Results (Patients
Without Need for
Biopsy)
93,765 (89,775 to 97,755) 92,120 (88,200 to 96,040)
1,748 (12) Moderate¶,#
Patients will receive reassurance that
they do not have a potentially
malignant or malignant disorder.
False-Positive
Results (Patients
Incorrectly
Classified as
Needing Biopsy)
5,985 (1,995 to 9,975) 5,880 (1,960 to 9,800) Patients would be identified
incorrectly as having a potentially
malignant or malignant disorder and
would undergo additional
unnecessary testing and biopsy.
* Setting: Primary care. Pooled sensitivity: 0.93 (95% confidence interval, 0.86 to 0.99). Pooled specificity: 0.94 (95% confidence interval, 0.90 to
0.98). Positive likelihood ratio, 16.14 (95% confidence interval, 8.15 to 31.94); negative likelihood ratio, 0.08 (95% confidence interval, 0.03 to
0.20). Sources: Delavarian and colleagues32 2010, Koch and colleagues35 2011a, Mehrotra and colleagues37 2008, Navone and colleagues40 2008,
Ng and colleagues41 2012, Rahman and colleagues42 2012, Sciubba44 1999, Fontes and colleagues33 2013, Kammerer and colleagues34 2013,
Nanayakkara and colleagues38 2016, Trakroo and colleagues47 2015, and Scheifele and colleagues43 2004.
† We estimated the prevalence by using data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program (300,682 people
living with oral cavity and pharynx cancer in the United States in 2013) and the 2010 census data for adults 45 years or older collected by the US
Census Bureau.
‡ The panel provided illustrative prevalence as an estimation of the number of histopathologic diagnoses from dysplasia to cancer.
§ GRADE: Grading of Recommendations Assessment, Development and Evaluation.
¶ Investigators conducted most studies in secondary and tertiary care settings. Most patients had a higher probability of having a malignant or
potentially malignant disorder.
# The positivity threshold for the criterion standard included from mild dysplasia to cancer in all studies except for that of Rahman and colleagues42
2012. The positivity threshold for the index test also included atypical results in the studies of Sciubba44 1999, Scheifele and colleagues43 2004, and
Rahman and colleagues42 2012.
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